Stockwinners Market Radar for February 17, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:21 EST Cathie Wood's ARK Investment bought 35K shares of Teradyne today

20:04 EST ConocoPhillips completes purchase of additional 10% shareholding in APLNG - ConocoPhillips announced through its Australian subsidiary that it has completed the purchase of an additional 10% shareholding interest in Australia Pacific LNG from Origin Energy for $1.645B. After customary closing adjustments, cash paid for the additional interest is approximately $1.4B. The transaction resulted from the exercise of ConocoPhillips' preemption right and is funded from cash on the company's balance sheet.

19:23 EST Snap CFO sells $1.04M shares of common stock - In a regulatory filing, Snap disclosed that its CFO Derek Andersen sold 26.1K shares of common stock in a total transaction size of $1.04M.

17:58 EST Pilgrim's Pride dives after Brazilian meatpacker JBS withdraws offer - Shares of Pilgrim's Pride fell $4.57 per share or 16.42% to $23.25 on Thursday evening, in post-market trading after Reuters reported that Brazilian meatpacker JBS "withdrew a proposal to acquire the remaining shares of its U.S.-based subsidiary Pilgrim's Pride."

17:25 EST Ellington Financial reports estimated book value per share of $18.17 on Jan. 31 - Ellington Financial announced its estimated book value per share of common stock of $18.17 as of January 31. This estimate includes the effect of the previously announced monthly dividend of 15c per share of common stock, payable on February 25 to holders of record on January 31, with an ex-dividend date of January 28.

17:11 EST Full House Resorts names John Ferrucci as COO - Full House Resorts "announced the promotion of John Ferrucci to the newly-created position of Senior Vice President and COO, subject to finalization of a new employment agreement between the Company and Mr. Ferrucci related to such position. As COO, Mr. Ferrucci will oversee the Company's efforts to open The Temporary at American Place until a permanent general manager is selected, continue to serve as General Manager of Silver Slipper Casino Hotel in Hancock County, Mississippi, and will oversee operations for the Company's other properties."

17:07 EST Roche awarded $212.5M Army contract modification - Roche was awarded a $212.5M modification to a contract for COVID-19 antigen test kits. Work will be performed in Indianapolis, Indiana, with an estimated completion date of May 31. American Rescue Plan Act funds awarded in FY22 in the amount of $212.5M were obligated at the time of the award. U.S. Army Contracting Command is the contracting activity.

17:06 EST Huntington Ingalls awarded $188.91M Navy contract modification - Huntington Ingalls was awarded an $188.91M cost-plus-fixed-fee modification to a previously awarded contract to continue performance of the repair, maintenance, upgrades, and modernization efforts on the USS Columbus engineered overhaul. Work will be performed in Newport News and is expected to be completed by December. FY22 operation and maintenance funding in the amount of $188.91M will be obligated at time of award and will expire at the end of the current fiscal year. The Supervisor of Shipbuilding is the contracting activity.

17:02 EST Marcus & Millichap initiates 25c per share semi-annual dividend - Marcus & Millichap announced that its board has declared an initial semi-annual regular dividend of 25c per share, or approximately $10.4M, payable on April 4 to shareholders of record as of the close of business on March 8. In addition, the board declared a special dividend of $1.00 per share, or approximately $41.7M, payable on April 4 to shareholders of record at the close of business on March 8.

16:57 EST Dropbox sees long-term gross margin 80%-82% - Sees long-term operating margin 30%-32%. Says has significant revenue and cash flow scale. Guidance taken from Q4 investor presentation slides.

16:46 EST Parsons in pact with Battelle to combine PFAS tools and technologies - Parsons Corporation announced that the company has entered into a collaborative agreement with Battelle Memorial Institute to combine Parsons' unique per- and polyfluoroalkyl substances investigation approach and tools with Battelle's patented PFAS analytical and site investigation tools and technologies. The combined capabilities will deliver a unique and highly advanced approach to help clients quickly, efficiently, and cost effectively investigate potential PFAS impacts and understand PFAS liabilities. PFAS is one of today's most significant environmental issues, and is being addressed around the world at aviation, industrial, manufacturing, and wastewater treatment facilities. The bipartisan Infrastructure Investment and Jobs Act allocates $10 billion in new funding to help communities investigate and mitigate PFAS and similar emerging contaminants in water and wastewater systems. "We recognize there is no one-size-fits-all approach to PFAS investigation, and our approach is complementary with Battelle's investigation technologies to produce extremely high quality data quickly and cost-efficiently," said Joe Cudney, senior vice president, energy and environment, for Parsons. "Our combined capabilities will provide a powerful PFAS investigation market discriminator, mitigating risks and liabilities through innovation, insight, and advocacy."

16:40 EST ICF International selected by Public Service Company of Oklahoma - ICF has been awarded a multimillion dollar recompete contract by the Public Service Company of Oklahoma to manage and implement its energy efficiency programs. PSO, a unit of American Electric Power, is an electric utility company serving more than 562,000 customer accounts in eastern and southwestern Oklahoma. As PSO's primary program implementer, ICF will serve as a strategic partner in managing the majority of the utility's commercial and residential portfolios. The company will provide a full suite of services including program design, program management and implementation, customer care rebate processing, call center support, database management and tracking, and more.

16:38 EST Sherwin-Williams names Heidi G. Petz as COO, effective March 1 - Sherwin-Williams announced that its Board of Directors has elected Heidi Petz to serve as President and COO effective March 1. Since 2020, Petz has served in senior leadership roles in The Americas Group, including the last year as President. In her new role, Petz will be responsible for all of Sherwin-Williams' operating segments, which includes The Americas Group, the Performance Coatings Group and the Consumer Brands Group, as well as the Global Supply Chain organization. Petz will continue reporting to John G. Morikis, who will continue to serve as Chairman and CEO. Petz has held numerous key leadership positions since joining Sherwin-Williams in connection with the acquisition of The Valspar Corporation in June 2017.

16:36 EST Cue Health, Cardinal Health partner on over-the-counter COVID-19 tests - Cue Health (HLTH) and Cardinal Health (CAH) announced expanded distribution of Cue's professional use and over-the-counter COVID-19 tests. Cue selected Cardinal Health, which serves nearly 90% of US hospitals and over 60,000 pharmacies, as one of its primary distributors due to a demonstrated expertise in helping commercialize diagnostic technologies. This relationship will help accelerate the reach of Cue's innovative nucleic acid amplification test into both traditional and non-traditional healthcare settings.

16:34 EST Clearway Energy increases quarterly dividend to $34.68 per share - Clearway Energy, announced that its Board of Directors declared a quarterly dividend on each of the Company's Class A and Class C common stock of 34.68c per share payable on March 15, to shareholders of record as of March 1. This quarterly dividend represents $1.3872 per share on an annualized basis, an increase of 2.0% over the fourth quarter 2021 dividend of 34c per share, or $1.36 per share annualized.

16:31 EST Middlefield Banc CEO Thomas Caldwell to retire, James Heslop to succeed - Middlefield Banc announced the company has appointed James Heslop as president and CEO, succeeding Thomas Caldwell. James Heslop, currently executive VP, COO and director of Middlefield Banc and The Middlefield Banking Company will assume the roles of president and CEO of both entities on April 1, upon Caldwell's retirement. Caldwell will also retire from the Middlefield Banc Corp. board of directors on March 31. The company's board of directors has taken action to reduce the size of its board of directors from ten to nine effective on April 1.

16:28 EST Financial Institutions boosts dividend 7.4% to 29c per share - Financial Institutions , parent company of Five Star Bank, SDN Insurance Agency, , Courier Capital, and HNP Capital announced that its Board of Directors has approved a quarterly cash dividend of 29c per outstanding common share, an increase of 2c or 7.4% from the most recent quarter.

16:26 EST Sandstorm Gold signs LOI with Royalty North Partners - Sandstorm Gold is pleased to announce that it has signed a letter of intent with Royalty North Partners Ltd. whereby RNP will acquire certain non-royalty and non-stream assets from Sandstorm, including the company's 30% equity interest in the Hod Maden project. In exchange, Sandstorm will receive a flagship $200M gold stream on the Hod Maden project, together with equity and debt consideration. The transaction will be a "Reverse Takeover" of Royalty North under the policies of the TSX Venture Exchange. Upon completion of the RTO, Royalty North will change its name to Horizon Copper Corp. or such other name as may be determined. Any following references to the "Resulting Issuer" or "Horizon Copper" are to Royalty North after the closing of the RTO.

16:24 EST Aspen Aerogels announces $150M investment from Koch Strategic Platforms - Aspen Aerogels announced that Koch Strategic Platforms, a subsidiary of Koch Investments Group, has agreed to make a $150M investment in Aspen through the purchase of convertible notes and common stock to support the company's aerogel thermal barrier growth opportunities. As part of the investment, KSP has agreed to purchase convertible notes in the aggregate principal amount of $100 million. The notes will have an initial conversion price of $34.936625 per share of Aspen common stock, subject to customary anti-dilution adjustments, which price is equal to 125% of the 10-day volume-weighted average price of Aspen common stock prior to the date of the note purchase agreement. Aspen has the right to settle its conversion obligations through the delivery of shares of common stock, cash, or a combination of cash and shares of common stock, at Aspen's election. The notes have a maturity date of February 18, 2027 unless earlier repurchased, redeemed or converted. Interest on the notes will be payable semi-annually, and Aspen is permitted to pay interest on the notes in cash or payment in-kind, at its election. Interest payments made in cash will be based on an interest rate of Secured Overnight Financing Rate plus 5.5% per year, and PIK interest payments will be based on an interest rate of SOFR plus 6.5% per year. Under the terms of the investment, SOFR has a floor of 1.0% and a cap of 3.0%. In addition, KSP has committed to certain standstill restrictions and Aspen has granted certain registration rights to KSP. In addition, KSP has agreed to purchase 1,791,986 shares of Aspen's common stock at a price of $27.902 per share, resulting in proceeds to Aspen of $50 million. The private placement of shares is subject to the satisfaction of customary closing conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 review. The private placement of shares is expected to close late in the first quarter or early in the second quarter of 2022.

16:23 EST Neximmune appoints Kristi Jones CEO - NexImmune announced that Kristi Jones has been appointed as the company's CEO and a member of its board. Her appointment follows the departure of Scott Carmer, who submitted his letter of resignation this week. Prior to her roles as Chief Business Officer and Chief Operating Officer at NexImmune, Jones spent more than 25 years in various strategic and operational leadership roles at AstraZeneca, Genentech and Eli Lilly.

16:22 EST Newpark Resources announces strategic review update - The company stated, "As part of the ongoing business and portfolio review, the Company announced that the Board of Directors recently approved two near-term actions intended to enhance liquidity available for investment in higher returning businesses, as the Company remains focused on taking the necessary steps to improve returns on invested capital and enhance long-term value for shareholders. These actions include winding down our industrial blending operations in the next few months and pursuing the sale of the industrial blending and warehouse facility and related equipment located in Conroe, Texas. Industrial blending contributed $9 million of revenues in 2021 while incurring a $2 million operating loss and ended the year with roughly $20 million of net capital employed. As a result of the plan to exit and dispose of the assets used in the Industrial Blending business, we may incur pre-tax charges in the range of approximately $4 million to $8 million primarily related to the non-cash impairment of long-lived assets, which we expect to recognize in the first quarter of 2022. Second, the Company will explore strategic options for the U.S. mineral grinding business, which supplies ground barite and other minerals to the U.S. Fluids Systems business, as well as to third parties in the oil and gas and industrial markets. The mineral grinding business contributed total third-party revenues of $36 million in 2021 yielding approximately break-even operating income and ended the year with $47 million of net capital employed, including roughly $25 million of net working capital."

16:22 EST CynergisTek announces multi-year managed cybersecurity service contracts - CynergisTek said it expanded on relationship with one of the six divisions of a prestigious academic healthcare system located on the west coast and adds a top-ranked hospital located in the southeast region to their growing client base. CynergisTek has renewed an agreement with one of its top customers to provide its signature Compliance Assist Partner Program service, which will provide the organization with ongoing cybersecurity services, advisory services, and executive reviews of the client's security infrastructure for another four years. CynergisTek has also signed a new agreement with a well-known independent nonprofit hospital to provide its Resilience Partner Program service, which will provide this client with ongoing cybersecurity services specifically focused on the client's medical device program enhancement for the next two years. "This team is focused on growth, and we are making steady progress towards that goal. Seeing our renewal rates approach pre-COVID levels is a good sign and having clients such as these reaffirm their confidence in our support with yet another renewal and an altogether new managed service relationship tells me we are doing the right things," said Mac McMillan, President & CEO of CynergisTek. "The market is receiving the new resilience approach positively and they are incorporating many of the new services that we have added in the last six months to their programs with several more to roll out shortly. These new services allow them to be much more proactive in their cybersecurity efforts," he says.

16:21 EST Matador reports 20% annual increase in total proved reserves - Matador Resources reported its estimated proved oil and natural gas reserves at December 31, 2021, which showed a 20% year-over-year increase in total proved reserves, including a 56% year-over-year increase in proved developed reserves, each as compared to the Company's proved oil and natural gas reserves at December 31, 2020. Joseph Wm. Foran, Matador's Founder, Chairman and CEO, commented, "Matador is pleased today to report a 20% year-over-year increase in our total proved reserves from 270.3 million BOE at December 31, 2020 to 323.4 million BOE at December 31, 2021, an all-time high for Matador. This reserves increase reflects the strong well results we continue to deliver across our various asset areas in the Delaware Basin and the significant improvement in the capital efficiency of our drilling and completions program in recent years. For the full year 2021, Matador's drilling and completion costs for all operated horizontal wells turned to sales averaged approximately $670 per completed lateral foot, a year-over-year decrease of 21% and an all-time low for Matador on an annual basis. Matador clearly delivered 'better wells for less money' in 2021. The Standardized Measure and PV-10 of our proved reserves at December 31, 2021 both increased significantly from a year ago. The Standardized Measure increased 2.8-fold from $1.58 billion at December 31, 2020 to $4.38 billion at December 31, 2021, and the PV-10 increased 3.2-fold from $1.66 billion at December 31, 2020 to $5.35 billion at December 31, 2021. At December 31, 2021, our proved oil and natural gas reserves were valued using an oil price of $63.04 per barrel and a natural gas price of $3.60 per MMBtu, an increase of 75% and 81%, respectively, as compared to $36.04 per barrel and $1.99 per MMBtu at December 31, 2020. Matador's proved oil and natural gas reserves at December 31, 2021 were also impacted positively by the increase in commodity prices used to estimate proved reserves at December 31, 2021, and particularly the 29% increase in our proved natural gas reserves, where the improved natural gas pricing contributed to longer economic well lives and increased reserves volumes."

16:19 EST Liberty Global sees FY22 adjusted EBITDA growth mid-single digits - The company said it expects to deliver mid-single-digit growth in Adjusted EBITDA, supported by improved top-line growth and the delivery of synergies, which will ramp through the year. Expected opex and capex costs to capture of over GBP300M and P&E additions of around GBP2.1B as the company accelerates network investments. Cash distribution to shareholders is anticipated to be GBP1.6B, including cash from recapitalizations to maintain leverage at the upper-end of the 4-5x range.

16:17 EST Fortive announces buyback of up to 20M shares - Fortive announced that its Board of Directors has authorized a share repurchase program under which Fortive may purchase up to 20M shares of Fortive's common stock. Under the repurchase program, Fortive may purchase its common stock on a discretionary basis from time to time on the open market or in privately negotiated transactions. The repurchase program has no expiration date and does not obligate Fortive to acquire any particular amount of shares, and may be suspended or discontinued at any time.

16:15 EST Merchants Bancorp raises quarterly dividend 17% to 7c from 6c per share - Available to shareholders of record on March 15, payable on April 1.

16:13 EST M/I Homes announces $100M increase to share repurchase plan - M/I Homes announced that its Board of Directors has approved an increase in its existing share repurchase authorization by an additional $100M. The company established its existing $100M share repurchase authorization in July 2021, and as of December 31, 2021, there was $48.5M of remaining availability under the authorization. With the increase, the company has increased the available authorization under the program to purchase up to $148.5M of its common shares.

16:12 EST Chuy's sees FY22 net capital expenditures $25M-$40M - The company said, "Due to the ongoing uncertainty around the magnitude and duration of the COVID-19 pandemic, the Company is not in a position to provide fiscal 2022 financial guidance, except the Company anticipates: Five to eight new restaurants vs. the previous range of six to eight new restaurants. Net capital expenditures (net of tenant improvement allowances) of approximately $25 to $40 million. Restaurant pre-opening expenses of approximately $2 to $3 million. An effective annual tax rate of approximately 13% to 15%."

16:11 EST Air Lease authorizes share repurchase program of up to $150M - On February 15, the Air Lease board of directors authorized a share repurchase program of up to $150M of its Class A common stock. The program expires on September 30, 2022. Also on February 15, the board of directors declared a quarterly cash dividend of 18.5c per share on its outstanding common stock that will be paid on April 7 to holders of record of its common stock as of March 18.

16:08 EST Realogy sees 2022 operating EBITDA $800M-$850M - 2022 guidance is based on year-over-year mid-single digit homesale transaction volume growth, closing of the pending sale of the company's title insurance underwriter, continued investment in strategic initiatives, absorption of increased agent commission costs, and achievement of targeted realized cost savings in 2022. Expects a return to historical seasonality patterns in 2022 - which have experienced disruption since the onset of the COVID-19 crisis. Consistent with typical seasonality patterns, and with Q1 typically being the smallest earnings quarter of our year, the company forecasts that Operating EBITDA generated in Q1 will be well below the unseasonably high Operating EBITDA delivered in 1Q21.

16:07 EST Exelixis: Cabozantinib franchise achieved $1.08B in U.S. revenues for FY21

16:04 EST FDA approves PMA supplement for Avita Medical's New RECELL System - AVITA Medical announced that the United States Food and Drug Administration, FDA, has reviewed and approved the premarket approval application PMA supplement for RECELL Autologous Cell Harvesting Device, an enhanced RECELL System aimed at providing clinicians a more efficient user experience and simplified workflow. The RECELL System is a device that enables healthcare professionals to produce a suspension of Spray-On Skin Cells using a small sample of the patient's own skin for the treatment of acute thermal burns. "To ensure RECELL continues to meet the needs of our customers, we initiated a program to explore how we could improve the device, and then addressed those matters with this new system," said Dr. Mike Perry, Chief Executive Officer of AVITA Medical. "Based upon research and human factors testing, we are confident that the new RECELL System will be positively received by the burn community. The enhancements will provide a range of benefits to clinicians using the device and in turn, patients will benefit as the procedure becomes more efficient. "..The launch of the new RECELL System in the United States will begin in Q2 2022. For more information about the RECELL System, please visit www.RECELLSystem.com.

15:42 EST Agios Pharmaceuticals says Pyrukynd FDA approval 'an encouraging step forward' - Agios Pharmaceuticals announced that the U.S. Food and Drug Administration has approved PYRUKYND in the U.S. for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare, debilitating, lifelong hemolytic anemia. PYRUKYND is a first-in-class, oral PK activator and the first approved disease-modifying therapy for this disease. "The successful ACTIVATE and ACTIVATE-T studies demonstrate the impact of mitapivat in significantly improving hemolysis and anemia in PK deficiency," said Hanny Al-Samkari, M.D., hematologist and clinical investigator at the Mass General Cancer Center and Harvard Medical School, and an investigator in these pivotal Phase 3 studies. "The FDA approval of mitapivat, a targeted agent and first disease-modifying medication in PK deficiency, is an encouraging step forward for these patients that addresses a significant unmet need."

15:21 EST SilverBox Engaged Merger Corp I trading halted, volatility trading pause

14:54 EST Cryptocurrency company Circle amends SPAC deal, doubles valuation to $9B - Cryptocurrency operator Circle Internet Financial said on Thursday it was valued at $9 billion under new deal terms with Concord Acquisition, a blank-check company backed by former Barclays boss Bob Diamond. According to a regulatory filing, the company terminated an earlier merger agreement with Concord, which had valued Circle at $4.5B, and amended the deal terms. "On February 16, 2022, immediately following the termination of the Business Combination Agreement, as described in Item 1.02 of this Current Report on Form 8-K, Concord Acquisition Corp, a Delaware corporation, Circle Internet Financial Limited, a private company limited by shares incorporated in Ireland, Circle Internet Finance Public Limited Company, a public company limited by shares incorporated in Ireland, and Topco Merger Sub, a Delaware corporation, entered into a Transaction Agreement, pursuant to which Topco agreed to combine with Concord in a business combination that will result in each of the Company and Concord becoming a wholly-owned subsidiary of Topco," the filing reads.

14:42 EST Agios Pharmaceuticals receives FDA approval of Pyrukynd - Agios Pharmaceuticals' Pyrukynd received FDA approval for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, according to a post to the agency's website. Reference Link

14:36 EST Faraday Future sees equipment 'setting stage' for FF 91 delivery in Q3 of 2022 - Faraday Future Intelligent Electric announced the arrival of intelligent manufacturing equipment from Guangzhou MINO Equipment Co., Ltd. stating that this shipment is "setting the stage for FF 91 delivery in Q3 of 2022." "Included in the shipment is critical equipment for the body assembly production line of the ultimate intelligent techluxury FF 91... The FF 91 Futurist Alliance Edition and FF 91 Futurist models represent the next generation of intelligent techluxury EVs. They are high-performance EVs that allow users to experience a luxurious, high-tech third internet living space beyond their home and office. Next week, FF will unveil the first production-intent FF 91 at its plant in Hanford, Calif. This achievement marks production Milestone #4 - production intent builds for final engineering validation and certification... Users can reserve an FF 91 Futurist model now," the company said.

14:30 EST Arena Group Holdings Inc trading halted, volatility trading pause

14:08 EST Nuvectis Pharma Inc trading halted, volatility trading pause

13:55 EST Crunchyroll app now available on Nintendo Switch - Crunchyroll, an anime streaming service and an indirect subsidiary of Sony (SONY), is now available on Nintendo Switch (NTDOY) consoles. "The Crunchyroll app is now available on Nintendo Switch, so you can stream all of your favorite anime on TV while your console is docked, or on the go with handheld and tabletop modes," Crunchyroll said. Reference Link

13:46 EST Coca-Cola board increases quarterly dividend 5% to 44c per share - The Board of Directors of The Coca-Cola Company approved the company's 60th consecutive annual dividend increase, raising the quarterly dividend approximately 5% from 42c to 44c per common share. The quarterly dividend is equivalent to an annual dividend of $1.76 per share, up from $1.68 per share in 2021. The first quarter dividend is payable April 1 to shareowners of record as of March 15.

13:33 EST Allianz takes EUR 3.7B charge amid talks with U.S. over hedge funds - Allianz announced that with respect to the pending court and governmental proceedings in the U.S. in relation to its Structured Alpha Funds, the company anticipates settlements with major investors in those funds shortly. In anticipation thereof and in light of current discussions with U.S. governmental authorities, Allianz decided to book a provision of 3.7B euros in its 2021 financial statements. This provision reduced the 2021 group net income by EUR 2.8B. "The anticipated settlements are an important step towards a resolution of the various proceedings. Discussions with remaining plaintiffs, the U.S. Department of Justice and the U.S. Securities and Exchange Commission remain ongoing and the timing and nature of any global or coordinated resolution of these matters is not certain," Allianz said in a statement.

13:20 EST Southern Company maintains long-term adjusted EPS growth view - Says EPS trajectory has "solid foundation." Says Georgia Power unit to add 6 gigawatts of renewables by 2035.

13:12 EST Southern Company says Vogtle unit delayed 3-6 months - Says a "reasonable" amount of capital budget being deployed on modernizing electric grid. Says Vogtle unit delayed 3-6 months, with costs rising $920M. Says carbon-free energy "vital" in reaching net zero emission goal. Comments taken from Q4 earnings conference call.

13:04 EST Cepton Inc trading halted, volatility trading pause

13:03 EST Eli Lilly says CMS decision 'could undermine promise of entire drug class' - Anne White, President of Lilly Neuroscience, has provided public comment to the Centers for Medicare & Medicaid Services to share Eli Lilly's perspective on the proposed National Coverage Decision for monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease. "We fear the proposed NCD undermines the promise of an entire drug class, contributing to unnecessary suffering and irreversible decline for people living with A. It's our duty to advocate for fair patient access based on clinical evidence to support patients, their caregivers and families. We are concerned that the proposed NCD will impede access to anti-amyloid therapies for several years as patients deal with an unrelenting progressive disease where severity will continue to advance. We urge CMS to revise the proposed NCD to provide automatic national coverage for on-label use of anti-amyloid treatments where confirmatory data demonstrate slowing of decline in cognition and function. Alternatively, CMS should issue NCDs on a drug-by-drug basis... We're strongly committed to additional data development for anti-amyloid treatments in new patient populations. If finalized, the proposed NCD will have a chilling effect on Alzheimer's research. If CMS makes Alzheimer's disease research investment unattractive, entities will shift investment to other diseases where these barriers do not exist. People with Alzheimer's disease will be the ones to suffer while they continue to wait for a cure," the statement reads.

12:38 EST Cathie Wood says Roblox one of best ways to play metaverse - Cathie Wood of ARK Invest is speaking on CNBC.

12:27 EST Joby falls after remotely piloted prototype aircraft gets in accident - Shares of Joby Aviation are falling after the company disclosed last night that one of its remotely piloted, experimental prototype aircraft was involved in an accident yesterday during flight testing at its remote flight test base in California. There were no injuries. "Experimental flight test programs are intentionally designed to determine the limits of aircraft performance, and accidents are unfortunately a possibility. We will be supporting the relevant authorities in investigating the accident thoroughly," Joby said in a regulatory filing. The U.S. National Transportation Safety Board is investigating the accident, which resulted in "substantial damage" to the aircraft, spokesmanPeter Knudsonsaid, according to Bloomberg. Shares of Joby are down 6% to $5.23 in midday trading.

12:21 EST TIG Advisors plans to vote against Zendesk's proposed acquisition of Momentive - TIG Advisors, LLC, an investment adviser which owns approximately 1.5 million shares of Zendesk, Inc. (ZEN) sent a letter to the Zendesk Board of Directors regarding its intention to vote "AGAINST" Zendesk's proposed acquisition of Momentive Global Inc. (MNTV), at the Company's Special Meeting of Stockholders to be held on February 25, 2022. The letter read, " We are writing to the Board of Directors to share our views on the proposed acquisition of Momentive Global announced on October 28, 2021. We plan to vote "AGAINST" the proposed acquisition. Zendesk shareholders have given the Company every opportunity to make their case in defense of the proposed acquisition of Momentive. Such opportunities have included an investor day, various conferences, earnings presentations, one-on-one meetings and nearly four months of our time. The market, however, has stood firm on its opinion of the transaction as illustrated by the depreciation of Zendesk's stock by 18% on the day the transaction was announced, and the further 5% tumble it took following the Company's November 18, 2021 Investor Day. We sought to share our opinion of the deal in a constructive manner, privately submitting a letter to the Board in December 2021, in which we stated that the Momentive transaction should be abandoned due to the overwhelming market reaction and the strong operating results of core Zendesk that would be diluted if a transaction were consummated. We put the Board on notice when we said that if the Company were to drag this process out to a shareholder vote in the face of such clear opposition it would erode trust in management. With the vote a little over a week away, we feel it now represents more than just a rejection of the Momentive transaction, but a referendum on the current leadership and direction of Zendesk. Since voicing our concerns directly to the Board in December, key fundamental shareholders, credible, independent third parties, ISS and Glass Lewis, and sell side analysts have all voiced strong opposition to the deal. There is a clear misalignment in vision between Zendesk leadership and the owners of the Company, its shareholders. We implore the Board to listen to shareholders at the upcoming vote and recognize that broad change is not only warranted but required. We note the Board nominations by Jana Partners, and believe it is in the best interests of the Company and its shareholders, that the Board avoid a monthslong proxy battle, and instead immediately install individuals to the Board who share a common vision with Zendesk's shareholders."

12:02 EST Norfolk Southern offers starting bonuses of up to $5,000 for conductor trainees - Norfolk Southern Corporation announced that it is offering starting bonuses of up to $5,000 for conductor trainees in priority locations, and $2,500 for other locations. Priority locations include: Binghamton, NY; Buffalo, NY; Cincinnati, OH; Louisville, KY; Manassas, VA; Harrisburg, PA; Conway, PA; Birmingham, AL; Sheffield, AL; Chattanooga, TN; Roanoke, VA; and Linwood, NC.

12:00 EST Informatica falls -29.9% - Informatica is down -29.9%, or -$8.42 to $19.73.

12:00 EST KAR Auction rises 13.2% - KAR Auction is up 13.2%, or $1.64 to $13.99.

12:00 EST U.S. Xpress Enterprises rises 15.6% - U.S. Xpress Enterprises is up 15.6%, or 54c to $4.01.

11:57 EST BNY Mellon being 'cautious' on buybacks, says CFO Portney - CFO Emily Portney is speaking at the Credit Suisse Financial Services Forum.

11:37 EST Novavax announces Health Canada authorization for COVID-19 vaccine - Novavax announced that Health Canada has granted authorization for Nuvaxovid COVID-19 Vaccine for active immunization to prevent coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 in individuals 18 years of age and older. "The vaccine, also known as NVX-CoV2373, is the first protein-based vaccine to be authorized for use in Canada," the company said. "Novavax and the Government of Canada signed an advance purchase agreement for 52 million doses of Novavax' COVID-19 vaccine, with the option for up to an additional 24 million doses, in January 2021 and established a memorandum of understanding to produce NVX-CoV2373 at the National Research Council of Canada's Biologics Manufacturing Centre in Montreal in February 2021. Novavax and the NRC have been working closely to establish the production of NVX-CoV2373 at the Biologics Manufacturing Centre. Good Manufacturing Practice production is expected to begin later this year," the company added.

11:24 EST Nissan to build two new EVs at Mississippi plant - Nissan said it will invest $500M to retool its assembly plant near Canton, Mississippi to begin U.S. production of two new electric vehicles starting in 2025 as part of the automaker's $18B program to expand its EV fleet through 2030. According to Nissan executives, the investment will include the addition of battery pack assembly operations in Canton. The automaker said it aims to have EVs make up 40% of its U.S. sales by 2030.

11:14 EST 'Stranger Things' creators reveal Season 4 date, renewal for final Season 5 - In an open letter to fans posted on the Netflix blog, "Stranger Things" series creators the Duffer Brothers revealed when new episodes will debut on Netflix and announced that a final Season 5 will be coming. The letter states in part: "Seven years ago, we planned out the complete story arc for Stranger Things. At the time, we predicted the story would last four to five seasons. It proved too large to tell in four, but -- as you'll soon see for yourselves -- we are now hurtling toward our finale. Season 4 will be the penultimate season; Season 5 will be the last." Volume One of Season 4 will release on May 27, the letter also noted. Reference Link

11:05 EST United Bancorp declares special dividend of 15c per share - The Board of Directors of United Bancorp, Inc. also approved a one-time, special dividend of $0.15 per common share, which is payable on March 18, 2022 to shareholders of record on March 10, 2022. The Board of Directors approved this special cash dividend based on the Company's continued solid earnings, ample liquidity and strong capital position. On a forward basis and inclusive of this special dividend payment, United Bancorp, Inc. is projected to pay cash dividends of $0.76 in the current year, as compared to $0.685 in 2021, an increase of $0.075 or 11.0%.

11:01 EST BlueLinx appoints Kevin Alan Henry as CPO - BlueLinx Holdings Inc. (BXC) announced the appointment of Kevin Alan Henry as Chief People Officer, effective March 1, 2022, and reporting to Dwight Gibson, President and CEO. Kevin was most recently the Executive Vice President, Chief of Staff to the CEO, and Chief People Officer at Extended Stay America (STAY).

10:50 EST US Foods trading resumes

10:43 EST Vistas Media Acquisition Company Inc trading halted, volatility trading pause

10:35 EST Flotek trading halted, news pending

10:08 EST Huntsman says Starboard waging 'unnecessary, disruptive' proxy contest - Huntsman announced that it has filed definitive proxy materials with the Securities and Exchange Commission in connection with its upcoming annual meeting of stockholders scheduled for March 25. Stockholders of record as of February 1, 2022, will be entitled to vote at the meeting. In conjunction with the definitive proxy filing, Huntsman has mailed a letter to the company's shareholders and the company summarizes the letter in part by stating: "Since September 2021, the Huntsman Board and management team have had over a dozen calls or meetings with Starboard. Huntsman offered to appoint one of Starboard's nominees to the Board, but Starboard was unwilling to agree to a reasonable negotiated resolution. After repeatedly endorsing Huntsman's strategy and execution, Starboard has refused to recognize our portfolio transformation and the Company's current strength. It is clear that there was, and continues to be, no misalignment with Starboard on the Company's objectives and strategic plan. In stark contrast with Huntsman's world-class Board, Starboard's nominees add no incremental value and lack relevant expertise to effectively serve on the Huntsman Board."

10:04 EST CME Group announces senior leadership changes - CME Group announced changes to its management team structure to position the company for long-term success. The new management team structure is detailed below, with all positions reporting to CEO Terry Duffy unless otherwise noted: Sunil Cutinho, who previously led CME Clearing and served in a variety of technology roles since joining the company in 2002, has been appointed Chief Information Officer. Overseeing the company's enterprise technology, Cutinho will replace Kevin Kometer who is retiring at mid-year. Julie Holzrichter, Chief Operating Officer, will assume an expanded role to oversee both global operations and CME Clearing. Holzrichter was appointed COO in 2014. Suzanne Sprague has been promoted to the management team as Senior Managing Director, Global Head of Clearing & Post-Trade Services, reporting to Holzrichter. Sprague has served as Managing Director, Credit, Collateral and Liquidity Risk and Banking for CME Clearing since 2015. Sean Tully will continue to lead the company's interest rates business, its largest asset class by revenue, as Senior Managing Director, Global Head of Rates & OTC Products. He is responsible for helping global clients navigate the ongoing market transition from LIBOR to SOFR-based products. He also will continue to oversee CME Group's cash and OTC businesses. Tim McCourt has been promoted to the management team as Senior Managing Director, Global Head of Equity and FX Products and will be responsible for overseeing equity, foreign exchange, cryptocurrency and alternative investment products. He has led the company's equity and alternative investment business since joining the company in 2013. CFO John Pietrowicz has announced his plans to retire in 2023. Lynne Fitzpatrick has been promoted to the management team as Deputy Chief Financial Officer and will succeed Pietrowicz upon his retirement. Fitzpatrick will work closely with Pietrowicz to ensure a smooth transition over the next year. She has served as Managing Director, Treasurer & Head of Corporate Development since 2017.

10:02 EST MGP Ingredients announces $12M barrel warehouse expansion - MGP Ingredients announced it has begun a $12M barrel warehouse expansion to meet growing consumer demand for its American whiskey. Construction of the new barrel warehouse facility has recently begun in Williamstown, Kentucky, and marks the company's second major investment in its distilled spirits operations in recent months. The warehouse expansion is located approximately 50 miles south of the company's historic Ross & Squibb Distillery in Lawrenceburg, Indiana. The project is slated for completion by the end of 2022. In late 2021, Luxco, operator of MGP's branded-spirits portfolio, announced a $4M expansion of its Lux Row Distillers facility in Bardstown, Kentucky. Slated for completion in late 2022, the expansion will allow Lux Row Distillers to operate 24 hours per day and increase its capacity by 75%.

10:00 EST Paymentus falls -20.4% - Paymentus is down -20.4%, or -$6.18 to $24.13.

10:00 EST Fastly falls -30.3% - Fastly is down -30.3%, or -$8.77 to $20.16.

10:00 EST DoorDash rises 14.0% - DoorDash is up 14.0%, or $13.24 to $108.13.

09:52 EST Bank of America CEO: Turnover rate in 2021 similar to 2019

09:51 EST Inspirato Inc trading resumes

09:47 EST Bank of America CEO: January spending 'very strong,' continuing in February - CEO Brian Moynihan is speaking at the Credit Suisse Financial Services Forum.

09:47 EST Bakkt falls -17.2% - Bakkt is down -17.2%, or -$1.35 to $6.49.

09:47 EST KAR Auction rises 14.1% - KAR Auction is up 14.1%, or $1.75 to $14.11.

09:47 EST DoorDash rises 17.7% - DoorDash is up 17.7%, or $16.79 to $111.68.

09:40 EST Camber Energy announces acquisition by subsidiary Viking Energy Group - Camber Energy announced on February 15, 2022 the acquisition by its majority-owned subsidiary, Viking Energy Group, of a 51% interest in entities that own the intellectual property rights to fully developed, patent pending, ready-for-market proprietary Electric Transmission and Distribution Open Conductor Detection Systems designed to detect a break in a transmission line, distribution line, or coupling failure, and to immediately terminate the power to the line before it reaches the ground.

09:38 EST Camp Pendleton Fire Department selects BK Technologies' BKR 5000 - BK Technologies Corporation announced that it has received a purchase order from Marine Corps Base Camp Pendleton for its new BKR 5000 portable communications technology, as part of their life cycle replacement program for the Camp Pendleton Fire Department.

09:35 EST 10x Genomics trading resumes

09:34 EST Sigma Labs appoints Jacob Brunsberg to president, COO - Sigma Labs has named Jacob Brunsberg to the position of President and Chief Operating Officer. Brunsberg will have responsibility for product direction, strategic relationships, sales, marketing, and engineering. As president, he will report to Mark K. Ruport, Sigma's CEO. Brunsberg will oversee several strategic initiatives designed to accelerate the growth and performance of the company, including the transition to a software only offering, initiating and implementing a comprehensive OEM integration program, building strategic partnerships, and implementing a new subscription-based pricing model. Each of these key initiatives is integral to lowering the additive manufacturing industry's technology adoption barriers and easing entry and expansion for manufacturers and OEM partners.Prior to joining Sigma Labs in September 2021 as Senior Vice President responsible for leading the company's strategic relationships, product management and marketing programs, Brunsberg was a P&L leader for General Electric's Binder Jet Technology unit with management responsibility for strategy, development, commercialization, and overall business performance

09:33 EST BioLargo provides progress report on growth catalysts - BioLargo provided an update on the progress of three important catalysts for commercial growth. 1) Garratt-Callahan / BioLargo Minimal Liquid Discharge Water Treatment System passes "factory acceptance testing": A commercial prototype of the new "minimal liquid discharge" water treatment system, invented by North America's largest privately held water treatment company, Garratt-Callahan, and engineered and built by BioLargo, passed the "factory acceptance" testing this week conducted by both BioLargo and Garratt-Callahan engineers at BioLargo's Oak Ridge, Tennessee facility. The new water treatment system is designed to reuse and recycle, rather than discharge, treated wastewater, resulting in lower operational costs and less environmental impact for customers. At this week's performance testing, the system removed over 98% of the target contaminants from water provided by a Garratt-Callahan client in continuous operation, in line with results achieved by Garratt-Callahan's original bench-scale and batch processing tests. This factory acceptance testing was a necessary step before commercial trials with Garratt-Callahan customers can begin. The first customer has already been identified, and the first on-site field trial for that customer is currently being planned. 2) PFAS treatment solution: Commercialization of BioLargo's revolutionary PFAS removal system, the "Aqueous Electrostatic Concentrator", or AEC, is progressing. While the company can't give details on confidential client communications, nor reveal details of new innovations, it has recently completed a series of further studies with a potential client's water to optimize technical and economic metrics and simulate the real-world conditions of a commercial trial. BioLargo's engineers are currently preparing a final techno-economic case study report for the client that will be integral for establishing in-field trials at the client's facilities, as well as at other prospective customers' sites. Additionally, BioLargo engineers recently completed in-house testing of the AEC using PFAS-contaminated water provided by BioLargo's a federal government agency. While internal preliminary testing shows the AEC eliminated PFAS from the water stream, the treated water samples have been submitted to the University of Tennessee for determinative analysis. On the commercial side, BioLargo is in discussions with both prospective customers and potential channel partners to develop and support sales and distribution of the AEC. 3) Pet odor control product: As previously disclosed, BioLargo and its strategic partner, Ikigai Marketing Works, LLC, are working together to support Ikigai's roll-out of a new pet odor control product based on BioLargo's proprietary technology. They have completed test marketing and their product orders from BioLargo thus far have exceeded the company's expectations. Ikigai is comprised of veteran consumer product executives with experience launching and growing multiple blockbuster consumer products. Both BioLargo and Ikigai are excited about the opportunities ahead for this and potentially other pet-oriented products.

09:31 EST Edesa Biotech reports enrollment milestone in Phase 2 ARDS study - Edesa Biotech provided an update on the Phase 3 part of a Phase 2/3 clinical study evaluating the company's monoclonal antibody candidate, designated EB05, as a single-dose therapy for hospitalized Covid-19 patients. Edesa reported that more than 25% of the subjects have been randomized to date under the Phase 3 protocol design approved by Health Canada. The enrollment milestone follows favorable Phase 2 results, which demonstrated compelling preliminary evidence of EB05's ability to reduce mortality in the sickest patients. Among the results, critically ill hospitalized Covid-19 patients given EB05 plus standard of care treatment had a 68.5% reduction in the risk of dying when compared to placebo plus standard of care at 28 days.

09:31 EST IBEX Limited trading halted, volatility trading pause

09:30 EST Energy Recovery receives industrial wastewater contracts totaling $885K - Energy Recover announced two awards to supply its PX(R) Pressure Exchanger energy recovery devices and an array of pumps to support industrial wastewater treatment operations at a battery-grade lithium carbonate manufacturing facility in Tibet, China and a textile wastewater treatment facility in Rajasthan, India. Both projects will utilize Energy Recovery's flagship PX in the seawater reverse osmosis desalination portion of their industrial wastewater treatment operations. The textile wastewater treatment facility in India will utilize a combination of Energy Recovery's PXs, turbochargers, and boosters to maximize efficiency. The operation in China is at one of the largest salt lakes in the world and will produce lithium carbonate, a crucial ingredient in lithium-ion batteries that power electric vehicles. Energy Recovery's PXs will help make treating industrial wastewater associated with lithium mining operations more energy efficient.

09:28 EST Carrier Global launches Carrier Ventures capital group for cold chain innovation - Carrier Global has created Carrier Ventures, a new global venture capital group focused on investments to accelerate the development of sustainable innovations and disruptive technologies enabling the future of building and cold chain management. Carrier Ventures aims to engage in deep collaboration and strategic partnerships with its portfolio companies, starting with its inaugural investments in AddVolt and OhmConnect - organizations committed to reducing global emissions from refrigerated transport and homes. AddVolt offers patented, non-invasive, low-maintenance electric systems for potential use with refrigerated vans, trucks, trailers and containers. In 2021, Carrier signed a strategic agreement with AddVolt to advance battery-electric transport refrigeration development. The technology is already being used by customers in Europe with the world's first fully autonomous electric trailer refrigeration system, the Vector eCoolTM.OhmConnect is a free service that rewards users for saving energy during times when demand on the electric grid is high, helping reduce electricity consumption and emissions. Users are rewarded for smarter energy use with points that can be redeemed in the OhmConnect Rewards Marketplace for discounts on Carrier products, prizes or cash via PayPal. Jennifer Anderson, Senior VP, Strategy, Business Development & Chief Sustainability Officer, will head Carrier Ventures. Anderson joined Carrier in 2021.

09:27 EST Cardlytics announces extendsion of PNC Purchase Payback - Cardlytics announced the extension of the PNC Purchase Payback, a loyalty program for PNC Bank, N.A., that provides customers rewards on every day purchases. The program originally began in 2011 and was expanded following PNC's acquisition of BBVA USA. Cardlytics now has relationships with four of the largest banks in the country, with insights into more than $3.5 trillion in annual consumer spend.

09:24 EST Clearmind to host 'Psychedelics for Alcoholism' event - Clearmind Medicine announced that as part of its highly attended "Psychedelics for Alcoholism" event series it will host market analyst Marissa Wright at a virtual event for investors. The online event will be held on February 23, 2022 at 12 p.m. EST and is open and free to all, Registration is required. Clearmind's last webinar attracted more than 1200 viewers. "Psychedelics for Alcoholism" Investor Deep Dive will provide investors a broad overview of the psychedelic treatments market with an emphasis on alcohol use disorders.

09:22 EST TripAdvisor says exited 2021 in 'much stronger position' - Says search for new CEO continues. Says will continue to invest in fintech. Says no plans for significant brand spend on TripAdvisor in FY22. Says "bullish" on 2022, sees return to "relatively normal traffic levels." Says "marked improvement" in February vs. January in the business. Comments taken from Q4 earnings conference call.

09:20 EST Sage Group says Vitamin Angels migrated to Sage Intacct - Sage announced that international public health organization Vitamin Angels recently migrated to Sage Intacct for a robust, cloud-based financial foundation. This helped the nonprofit improve accounts payables efficiency by 60 percent, eliminate accounts receivables data entry, and gain the visibility and insights required to increase its restricted revenue by $14 million over three years.

09:19 EST Rigetti Computing reports fidelities as high as 99.5% on chip architecture - Rigetti Holdings announced it has achieved entangling gate fidelities as high as 99.5% on its next-generation chip architecture, crossing what is believed to be a key threshold for commercial quantum computing. The results follow the company's recent announcements on scalability and speed on its production systems, relating to Rigetti's progress toward quantum advantage and fault-tolerant quantum computing. Today's quantum computers are prone to errors, which limit the size and complexity of problems that can be encoded and processed on them. Reducing these errors is the focus of many efforts across the industry, and is widely believed to be one of the key characteristics for commercial quantum computers, along with scale, speed, reprogrammability, and co-processing. The next-generation chip architecture builds on several engineering achievements from its previous generation processors, including 3D signal delivery and superconducting caps and vias, which are designed to reduce crosstalk among qubits on the chip. It also incorporates recent advances in qubit design and gate operations, which the company has published previously. Internal measurements on a 9-qubit test device demonstrate two-qubit gate fidelities as high as 99.5% and a median fidelity of 99.2%

09:16 EST Avantax acquires Gene Bell & Associates, terms not disclosed - Avantax has acquired Washington-based Gene Bell & Associates. The transaction expands the presence of Avantax's employee-based RIA, adds venerable tax expert and Financial Professional Gene Bell, CFP, E.A., NTPI Fellow, to the financial services company's management team, and helps ensure Bell's clients are well-served as they pursue their financial goals. Bell joins Avantax as Director, Tax-Smart Initiatives, reporting directly to Andy Watts, Vice President, Investment Solutions; three of Gene Bell & Associates' talented staff also become Avantax employees. Having been affiliated with Avantax for several years, this transaction enables Bell to contribute full-time toward the Avantax vision to profoundly impact clients' lives by changing the way Americans plan and invest. Bell's new role includes further expanding the Tax-Smart Investing tools that Avantax develops to help create value for Financial Professionals and their clients who believe in planning their financial future from the intersection of tax and financial planning.

09:15 EST Mayfair Gold announces maiden ESG rating from Digbee - Mayfair Gold is pleased to announce receipt of the Company's maiden environmental, social and governance ratings report from Digbee ESG. Digbee is a leading independent assessment platform for ESG disclosure in the mining industry. Based on ESG achievements in the Company's first year of operations at the Fenn-Gib gold project in the Timmins region of Northern Ontario, Mayfair achieved an overall rating of BB. Digbee's report provides a comprehensive assessment of Mayfair's achievements across a broad range of key ESG performance criteria. The report is especially valuable in highlighting opportunities for improvement in specific areas. As Mayfair strives for continuous improvement, a mid-year reassessment under Digbee will be undertaken.

09:12 EST Shineco enters strategic alliance with JSY - Shineco announced that on February 16, 2022, the Company entered into a strategic cooperation framework agreement with Beijing Jinshengyun Pharmaceutical Technology, a Beijing-based outsourcing service company engaged in comprehensive drug and medical device development, for in-depth cooperation in the research and development of innovative drugs and medical devices. Both parties plan to promote innovative drugs and medical devices and support the establishment of Shineco pharmaceutical R&D and innovation center. JSY is a professional outsourcing service company engaged in comprehensive drugs and medical devices development. JSY is dedicated to providing drug and medical device clinical trials, R&D, project management, and project risk assessment for Chinese and international pharmaceutical companies. JSY has achieved the modern management of clinical trials and provided qualified solutions for clinical trials through the application of digital technology and system. JSY's team has expertise on fulfilling the requirements of International Conference on Harmonisation-Good Clinical Practice, China's National Medical Products Administration-Good Clinical Practice and domestic and international regulatory, and rich experience in clinical research and management. As a strategic industry related to the people's livelihood and economic development, the pharmaceutical industry is an important foundation for constructing the "Healthy China 2030" project. According to the "14th Five-Year Pharmaceutical Industry Development Plan" issued by the Chinese government, the development of biomedicine and the improvement of the supply guarantee system for medical devices are included in the next development goals. Both parties will seize these opportunities to increase market share in the innovative drug and medical device industry by relying on their business advantages and the synergy of their cooperation.

09:08 EST Cerner partners with Social Security Administration for disability claims - Cerner announced a new agreement with the Social Security Administration to help simplify patient disability benefits claims through secure, clinical electronic health record retrieval from health systems. The new agreement between Cerner and the SSA aims to speed the transfer of relevant, patient-directed medical records from the health system to the SSA, potentially cutting transfer times from weeks or months to seconds or minutes. Cerner and SSA's collaboration to automate data aims to ease administrative burdens, reduce costs and labor and eliminate the mailing of paper records.

09:07 EST Applied DNA Sciences, EvviVax present preclinical data for LinearDNA - Applied DNA Sciences and its program development partner, EvviVax, announced the publication of a manuscript detailing a preclinical study showing that LinearDNA vaccines used for cancer immunotherapy produced a strong immune and specific antitumoral response in preclinical mouse models. The study investigated the use of the LinearDNA platform to produce DNA vaccines targeting either tumor-associated antigens or tumor-specific antigens. The manuscript, "Linear DNA Amplicons as a Novel Cancer Vaccine Strategy," is published online on the bioRxiv.org preprint server and has been submitted for peer-reviewed publication. LinearDNA is Applied DNA's proprietary, large-scale polymerase chain reaction -based manufacturing platform that allows for the large-scale production of specific DNA sequences. DNA vaccines that target TAAs hold promise as potential pan-cancer vaccines that, when used in conjunction with existing standards of care, can increase the efficacy of cancer immunotherapies. DNA vaccines targeting TSAs, otherwise known as personalized cancer vaccines, also hold great promise in immunotherapy as they can be customized to induce an immune response only against a patient's tumor, thereby limiting on-target, off-tumor effects.

09:06 EST Bird Global announces permit extensions, increased fleet in select U.S. markets - Bird Global announced it has secured permit extensions for its shared micro-electric vehicle offerings in Long Beach, California, Portland, Oregon and Decatur, Georgia. The company also announced it is increasing its fleet sizes in Durham, North Carolina, Isla Vista, California and Arlington, Virginia, as more students return to campus and seek eco-friendly personal transportation.

09:05 EST Allbirds teams with branded recommerce firm Trove to launch 'ReRun' - Allbirds announced the launch of Allbirds ReRun, a new resale platform, in partnership with Trove . ReRun is part of Allbirds' holistic commitment to sustainability and will initially offer customers at three stores the option of trading in their preloved Allbirds shoes for $20 in store credit. Following the launch in Los Angeles, Chicago and New York City, the brand plans to expand the program to additional retail locations nationally. "Since its founding, Allbirds has been a global leader in end-to-end sustainability that is raising the bar for the entire retail industry," said Andy Ruben, CEO of Trove. "The company has set a goal of doubling the lifetime of its footwear products and we could not be prouder to partner with Allbirds to power ReRun as the company moves another step forward toward fully circular operations." The new recommerce program ties closely to Allbirds' Flight Plan, a series of sustainability commitments that include reducing the brand's per-product carbon footprint by half by the end of 2025 and cutting it to near zero by the end of 2030. Through its partnership with Trove, Allbirds will prolong the life of its products, which is a key component of Allbirds' sustainability strategy. Allbirds is already a 100% carbon-neutral business through the use of third-party verified carbon offsets. "To create a more sustainable fashion economy, it's crucial that we take a holistic approach," said Hana Kajimura, Head of Sustainability at Allbirds. "By launching our trade-in program, ReRun, we will enable our customers to play an integral role in extending the life of our shoes. We always seek partners who share our commitment to sustainability, and we're thrilled to work with Trove on our first recommerce initiative."

09:03 EST Renewable Energy to install pretreatment facility in Germany - Renewable Energy announced it will install a pretreatment facility in Germany, enabling the company to refine some of the lowest carbon intensity, hardest to convert waste fats and oils for bio-based diesel production. The project is located on the North Sea harbor of Emden, Germany at the border to The Netherlands. This project will enhance REG Emden and REG Oeding's ability to produce renewable fuel from a wider variety of feedstocks, including 'Generation 3' advanced feedstocks as defined under the Renewable Energy Directive, or RED, II. This strategic upgrade will enable the company to continue to expand the company's strong global sourcing and trading position, produce more deeply decarbonized fuel and better serve European customers seeking to accelerate their transition to cleaner energy.

09:02 EST Streamline Health appoints Ben Stilwill as CEO, president, eValuator Solutions - Streamline Health Solutions announced that Ben Stilwill, previously Senior Vice President of Customer Success, has been promoted to President & CEO, eValuator Solutions, reporting to Tee Green, effective immediately. Amy Sebero, a 28-year veteran of nThrive Revenue Systems, LLC, most recently as Chief Growth Officer responsible for SaaS revenue in excess of $220 million, will join the company as Chief Growth Officer, eValuator Solutions, effective March 14, 2022. Ben Stilwill has been Streamline's Senior Vice President of Customer Success since 2020 and has developed a world-class customer success organization within eValuator focused on maintaining key client relationships and establishing a stable of referenceable accounts. In addition, the role of Lance Seach, Senior Vice President of Business Development, has been expanded to lead business development efforts for both the eValuator and Avelead organizations. The Company also announced today that Randy Salisbury has also been appointed to serve as Senior Vice President of Investor Relations.

09:01 EST Evoke Pharma announces outcomes of research study for Gimoti - Evoke Pharma announced outcomes from an additional research study conducted for GIMOTI nasal spray. The study's objective was to assess the overall awareness of and familiarity with GIMOTI across a broad spectrum of healthcare providers. The company also announced the availability of recently recorded patient testimonial videos and a recent positive insurer decision for New York State Medicaid. Research Study In December 2021, Evoke's commercialization partner EVERSANA conducted a GIMOTI Awareness, Trial, and Usage Study to gauge continued physician and provider awareness, trial, and utilization of GIMOTI following market developments in the second half of 2021. Similar to previous studies, this survey was divided into four sections: the current treatment approach, recent prescribing behavior, treatment awareness, and additional perspectives around support resources. The survey participant population of 135 respondents was comprised of 65 gastroenterologists targeted by Evoke sales professionals, 25 non-target GIs, 25 non-target primary care physicians, and 20 non-target GI-affiliated nurse practitioners and physician assistants. Key findings from the survey include: Steady increase in intent to prescribe GIMOTI; 88% of all respondents intend to prescribe GIMOTI; 92% of targeted GIs compared to 90% in previous study; 92% of non-targeted GIs compared to 86% in previous wave; 80% of PCPs compared to 100% in previous study; 89% of NP/PAs; increased sample size since previous study; Increase in proportion of patients using GIMOTI in any line of therapy; Wider acceptance especially among GIs as first-line usage for patients with severe gastroparesis; Greater usage of GIMOTI as third-line therapy showing significant increase by GIs of 33.3% from previous waves; Scored higher familiarity rates among all GIs and NPs/PAs; over 80% of target and non-target GI respondents show robust awareness of GIMOTI. Respondents across all segments perceive an oral tablet as the least effective route of administration. Evoke and Eversana continue to introduce the benefits of GIMOTI to various public and private insurers. Recently, GIMOTI has been added to the New York State Medicaid program for coverage requiring only proof of diabetes diagnosis.

08:59 EST SurgePays enables consumers to purchase bitcoin in stores - SurgePays announced the full roll out of its Bitcoin sale software platform. The SurgePays' software platform has enhanced its ability to serve the underbanked in the community by enabling store owners to sell Bitcoin to customers - with or without a bank account or credit card. Store owners can sell Bitcoin at local convenience and neighborhood stores which are part of the Company's 8,000-plus and growing retail store network. SurgePays' new feature will allow the store clerk to facilitate the purchase of between $50 to $1,499 of Bitcoin.

08:56 EST Celsion reports DSMB recommendation to continue dosing in Phase II of OVATION 2 - Celsion Corporation announced that following a pre-planned interim safety review of 81 as treated patients randomized in the Phase I/II OVATION 2 Study with GEN-1 in advanced ovarian cancer, the Data Safety Monitoring Board has unanimously recommended that the OVATION 2 Study continue treating patients with the dose of 100 mg/m2. The DSMB also determined that safety is satisfactory with an acceptable risk/benefit, and that patients tolerate up to 17 doses of GEN-1 during a course of treatment that lasts up to six months. No dose-limiting toxicities were reported. The OVATION 2 Study combines GEN-1, the Company's IL-12 gene-mediated immunotherapy, with standard-of-care neoadjuvant chemotherapy in patients newly diagnosed with Stage III/IV ovarian cancer. NACT is designed to shrink the cancer as much as possible for optimal surgical removal after three cycles of chemotherapy. Following NACT, patients undergo interval debulking surgery, followed by three additional cycles of chemotherapy to treat any residual tumor. The OVATION 2 Study is designed with an 80% confidence interval for an observed Progression Free Survival Hazard Ratio of 0.75, which would mean an approximate 33% improvement in risk for cancer progression when comparing the treatment arm with the control arm. GEN-1 is an immunotherapy that produces safe and durable local levels of IL-12, a pluripotent cytokine associated with the stimulation of innate and adaptive immune response against cancer. The GEN-1 nanoparticle comprises a DNA plasmid encoding IL-12 gene and a synthetic polymer facilitating plasmid delivery vector. Cell transfection is followed by persistent, local secretion of the IL-12 protein at therapeutic levels. The Company also announced that more than 75% of the projected 110 patients have been enrolled in the OVATION 2 Study. Interim clinical data from the first 39 patients who have undergone interval debulking surgery showed that the GEN-1 treatment arm is showing a 27% improvement in R0 surgical resection rate over the control arm. A complete tumor resection is a microscopically margin-negative resection in which no gross or microscopic tumor remains in the tumor bed.

08:54 EST Maris-Tech to co-develop video-based advanced AI systems for drones, AVs - Maris-Tech announced it has signed a letter of intent with a fabless semiconductor supplier to develop video-based edge computing products. The products will utilize Maris-Tech's Jupiter Nano, a part of the Jupiter series, a low latency video encoding and decoding platform designed to handle multiple video channels. Jupiter delivers real-time intelligence gathering and analytics-based situational awareness capabilities, featuring intelligent video transmission technologies with high quality video, superior energy efficiency, and miniaturized form factors suitable for a wide range of platforms and applications. Jupiter will be combined with an artificial intelligence component designed by the fabless semiconductor supplier to create a new product that will potentially enhance a drone's ability to gather visual intelligence in military and commercial applications. It will enhance target identification and act as an accelerator to enable customers to run efficient intelligence algorithms and improve the performance of the AI. The target applications for the products will be indoor and outdoor drones, unmanned miniature ground vehicles, loitering munitions, observation systems, high-end sights, autonomous vehicles and situational awareness devices. The products will be designed to meet requirements of manned and unmanned platforms equipped with high resolution video sensors for video recording, debriefing and low-latency streaming as well as high-end video-based AI capabilities. The products will also meet requirements for miniaturization, low weight and low power.

08:52 EST Taoping enters LOI to acquire majority ownership of Fujian Taoping - Taoping announced that it has entered into a letter of intent with the shareholders of Fujian Taoping IoT Technology Limited to acquire at least 51% of the ownership of Fujian Taoping. Pursuant to the LOI, the purchase price, to be determined by the parties after the completion of due diligence of Fujian Taoping, will be paid in the form of ordinary shares of TAOP. The LOI will be automatically terminated if no definitive agreements are entered into among the parties before December 31, 2022. Established in May 2017, Fujian Taoping has served over 2,000 customers so far. As of February 2022, Fujian Taoping's self-operated and investment areas cover seven major cities in Fujian Province, including Fuzhou, Quanzhou, Zhangzhou, Nanping, Putian, Sanming, and Longyan. Currently, Fujian Taoping's network has a total of 8,899 smart screen locations, covering more than 700 high-end residential areas, commercial centers, and office buildings. It laid a good foundation for the subsequent expansion of the smart community service in the local area. After the closing of the acquisition, Fujian Taoping is expected to become an important part of Taoping Digital Culture East China Operation Center. While continuing to grow the current business, Fujian Taoping plans to take advantage of its existing channels to expand the business of smart charging piles, smart stations, large-screen splicing displays, and build an integrated digital service ecosystem.

08:50 EST Fluidigm enters collaboration agreement with Abu Dhabi Stem Cells Center - Fluidigm Corporation announced a collaboration agreement with the Abu Dhabi Stem Cells Center for development of targeted stem cell therapies and research applications utilizing two Fluidigm mass cytometry and tissue imaging technologies: Imaging Mass Cytometry and the Maxpar Direct Immune Profiling Assay. The ADSCC, founded in 2019, is a specialist health care center that focuses on cell therapy and regenerative medicine in addition to cutting-edge stem cell research. The Center collects, processes, characterizes, and stores cell products for clinical application in both regenerative medicine and hematopoietic transplantation. The ADSCC collaboration with Fluidigm represents an opportunity to increase the visibility of mass cytometry technology for potential new customers in the Middle East and to establish a foundation for expansion in the region. IMC provides researchers with a better understanding of cells' spatial environment to answer important translational and clinical research questions relating to disease. The Fluidigm Maxpar Direct Immune Profiling Assay was the first complete sample-to-answer solution for high-dimensional immune profiling of blood samples. Fluidigm's immune profiling solution encompasses reagents, the CyTOF mass cytometry system, and analytical tools to deliver an analysis of 37 immune cell populations. As part of the collaboration, the ADSCC will: receive early access to reagents and software under development by Fluidigm; evaluate pre-released Fluidigm materials and products under development; participate in Fluidigm events and host visits or experiments by Fluidigm customers or prospects relating to the Helios system and the Hyperion Imaging System, which use CyTOF technology; and participate in product development discussions with respect to Helios and the Hyperion Imaging System.

08:48 EST Atlas Air enters long-term agreement with Kuehne & Nagel for Boeing freighters - Atlas Air announced it has entered into a long-term, dedicated charter agreement to operate two of its new incoming Boeing 747-8 freighters on a global basis for Kuehne+Nagel, one of the world's largest freight forwarders. Atlas Air will commence operation of these aircraft for Kuehne+Nagel following their delivery from Boeing, with one expected in the third quarter and the second in the fourth quarter of 2022. Atlas Air operates one of the world's largest fleets of 747-8Fs, the most capable freighter aircraft in the world. These two aircraft placed with Kuehne+Nagel are the last 747s Boeing will produce.

08:46 EST Phunware launches PhunToken liquidity pool rewards program - Phunware announced today the launch of its PhunToken liquidity pool rewards program for an Ether - PHTK trading pair at Uniswap V2. PHTK is currently available for purchase here with US Dollars, Bitcoin or ETH. The liquidity pool rewards program is expected to launch next month and the first reward will be distributed in April to eligible whitelisted wallets. These rewards are paid in PHTK to every eligible liquidity provider that locks ETH and PHTK on Uniswap for at least 30 days. These rewards are in addition to the anticipated 0.3% fee liquidity providers typically get from Uniswap trades on trading pairs they provide liquidity to in the market. Only a limited number of liquidity providers who register here will be whitelisted.

08:44 EST Assure Holdings appoints Brian McDonald as VP, business operations - Assure Holdings announced that Brian McDonald was appointed vice president of business operations. As Assure's vice president of business operations, Mr. McDonald will be responsible for the development and execution of corporate strategy initiatives to drive growth and improve business performance. He will work closely with the executive leadership team to identify, analyze and resolve business challenges and capitalize on new growth opportunities, including mergers and acquisitions. In addition, Mr. McDonald will lead efforts to cohesively scale Assure's finance, operations and sales cross functionally. Prior to joining Assure, Mr. McDonald's experience included serving as chief financial officer and treasurer at Health Fidelity.

08:42 EST Yeti winding down relationship with Lowe's, doesn't see 'any material impact' - Yeti CEO Matthew Reintjes stated on the company's Q4 earnings call: "Demand in our Wholesale channel was strong throughout the quarter, highlighting the importance and strength of this channel at all levels. As discussed last quarter, we reduced our independent Wholesale footprint to approximately 3,000 target accounts, which we believe helps focus our efforts on very high caliber retail to drive consistent, high-quality experiences for our customers. As has been our practice, we continue to look to strengthen the Wholesale channel with a focus on many of the incredible and long-standing partnerships we have developed across the independent, regional and national account levels going back to 2006. Consistent with that effort, we have made the decision to thoughtfully wind down our relationship with Lowe's. To be clear, Lowe's has been a great partner, and has worked closely with us as we have continuously experimented with how to best serve their customers and shopper patterns. However, as we have evaluated our growth areas, our focus and optimization mandate and the current supply constraints, we ultimately believe we can be more productive, better serving our Yeti customers across our strong existing Wholesale partnerships, our owned direct channels and our growing international opportunities. We do not expect any material impact from this change as we fully reallocate inventory to support demand across the previously mentioned channels."

08:40 EST Genuine Parts reports Q4 Automotive Parts Group SSS up 10.6% - Sales for the Automotive Group were $3.2B in the fourth quarter, up 13.1% from 2020 and representing 66% of total company revenues. The improvement was due to a 10.6% global increase in comparable sales and a 2.8% benefit from acquisitions, net of a slightly unfavorable impact of foreign currency and other. Segment profit of $265.8M was up 10.7% and the profit margin was 8.3% compared to 8.5% in the same period of 2020. Sales for the Industrial Parts Group were $1.6B, up 12.8% from 2020 and representing 34% of total company revenues. The improvement reflects a 12.5% increase in comparable sales and a 0.3% favorable impact from foreign currency. Segment profit of $153.8M was up 15.3% and the profit margin was 9.5% compared to 9.3% in 2020, up 20 basis points. "The double digit sales and earnings growth for the Automotive and Industrial businesses is a reflection of strong global demand and the diligent execution of our initiatives to accelerate growth and improve profitability," CEO Donahue said. "The strength in Automotive was broad-based across our operations, with 13% sales comps in the U.S. and high-single digit sales comps in Canada, Europe and Australasia. Likewise, we had strong growth in both our North American and Australasian Industrial businesses, which drove the third consecutive quarter of double digit comps for this segment."

08:38 EST Natera's Prospera kidney test shows predictive efficacy in study - Natera announced the results of a large, real-world study confirming strong performance of its Prospera donor-derived cell-free DNA test in assessing rejection for kidney transplant patients. The study, published in Transplantation Proceedings, reports the real-world impact of dd-cfDNA on patient management in a multi-center, real-world clinical cohort, including 879 patients evaluated from 33 participating clinics. Eighteen of the 28 patients with biopsy-matched high-risk Prospera dd-cfDNA test results were confirmed to have active rejection, demonstrating a reported 64% positive predictive value. As summarized in the publication, "The data indicate that incorporating dd-cfDNA testing into practice may improve physician decision making regarding renal allograft recipients."

08:37 EST Genuine Parts reports Q4 increase in comparable sales of 11.3% - Sales were $4.8B in Q4, a 13.0% increase compared to $4.3B in the same period of the prior year. The improvement is attributable to an 11.3% increase in comparable sales and a 1.9% benefit from acquisitions, partially offset by a slightly unfavorable impact of foreign currency and other.

08:36 EST Navitas Semiconductor, UGREEN announce GaNFast global marketing program - Navitas Semiconductor has announced a GaNFast Global Marketing Program with consumer electronics and accessory specialist UGREEN. The program builds on the companies' technology partnership to create awareness of GaN and education for global consumers. Under the new program, UGREEN invited Navitas to participate in the live broadcast launch of the company's new 100W four-port GaN charger. Navitas' GaNFast power ICs integrate GaN power and drive plus protection and control. Additional cooperation to increase global consumer awareness of GaN and associated charger products include enhanced product promotion via the companies' official websites, social media channels, conference/trade show booths including CES2022, and video displays on the Nasdaq building in Times Square, New York.

08:35 EST NFI Group announces 130 BYD ADL electric double deck bus order - NFI Group, subsidiary Alexander Dennis Limited and BYD UK jointly announced that their electric vehicle partnership will supply over 130 battery-electric double deck buses to EV fleet and battery storage specialist Zenobe and National Express, and will support these vehicles with spare parts over a period of 16 years. The deal will see over 130 BYD ADL Enviro400EV double deck electric buses, all manufactured in Britain by ADL in partnership with BYD, enter service in Coventry from early 2023 as a part of the city's successful bid to become the country's first all-electric bus city and take it a huge step closer to replacing around 300 diesel vehicles by 2025. Zenobe will be providing Electric Transportation as a Service to National Express, financing and managing the full turnkey solution that includes new BYD ADL vehicles, on-board battery replacement, charging and grid infrastructure, a second-life battery system at the depot, unique software to optimise charging, parts, and full operational support. As part of the agreement, ADL will supply Zenobe and National Express with spare parts for planned preventive maintenance over a period of 16 years from acceptance of the vehicles.

08:34 EST Gracell doses first patients in clinical trial of lymphoma candidate GC012F - Gracell has dosed multiple patients in a clinical trial evaluating GC012F, the company's autologous CAR-T therapeutic candidate dual-targeting B cell maturation antigen and CD19 in B-cell non-Hodgkin's lymphoma, or B-NHL. NHL is the fifth most common cancer in the U.S. The Phase 1 trial conducted in China is a first-in-human study evaluating FasTCAR-enabled BCMA/CD19 dual-targeting GC012F for the treatment of relapsed or refractory B-NHL. GC012F, developed using Gracell's proprietary FasTCAR platform which enables next-day manufacturing, GC012F is currently also being evaluated in IIT studies in China including relapsed/refractory multiple myeloma. In November 2021, GC012F was granted Orphan Drug Designation by the FDA.

08:33 EST Genuine Parts sees FY22 net cash from operating activities $1.5B-$1.7B - Sees FY22 free cash flow $1.2B-$1.4B.

08:32 EST Yumanity Therapeutics plans to eliminate 60% of workforce - The Board of Directors has approved a strategic restructuring with the objective of preserving capital. As part of the restructuring, the Company anticipates eliminating approximately 60% of its workforce, to be completed by April, among other actions to reduce cash burn while the Company explores strategic alternatives. The Company also expects to incur a non-recurring charge of approximately $0.4 million in the first quarter of 2022 related to the restructuring.

08:30 EST Arvinas announces Phase 1, interim Phase 2 data for bavdegalutamide - Data from these trials will be presented in both a rapid abstract session and a poster session on February 17, 2022, at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium. Highlights from the Phase 1 and interim Phase 2 ARDENT data" PSA50 rate of 46% in patients with AR T878X/H875Y tumor mutations; Two durable confirmed RECIST partial responses out of seven RECIST-evaluable patients with AR T878X/H875Y tumor mutations; PSA reductions and evidence of anti-tumor activity as measured by RECIST were observed across all subgroups regardless of mutation status, including in patients with tumors not harboring AR T878X/875Y mutations; PSA50 rate of 22% in evaluable patients in the subgroup defined as "less pretreated". A majority of patients with PSA50 declines in this group had tumors with the AR T878X/H875Y mutations. Bavdegalutamide had a manageable tolerability profile at the recommended Phase 2 dose of 420 mg oral, once daily. Most treatment-related adverse events were Grade 1/2 and there were no Grade greater than or equal to4 TRAEs in the 138 patients treated at the RP2D. Arvinas intends to initiate discussions with the U.S. Food and Drug Administration about the potential for an accelerated approval pathway with bavdegalutamide in a molecularly defined mCRPC population. The Company also plans to initiate a pivotal trial by year end. Future studies will be planned to explore the potential to treat earlier-line patients who may benefit from bavdegalutamide therapy. Bavdegalutamide Clinical Update: Enrollment: As of the data cut-off date of December 20, 2021, 195 patients were enrolled across the Phase 1/2 clinical trial. The Phase 1 dose escalation trial evaluated bavdegalutamide at doses ranging from 35-700 mg, orally, once-daily, or 210-420 mg twice-daily in patients with mCRPC and greater than or equal to2 prior therapies. The ARDENT Phase 2 dose expansion trial was administered at a starting dose of 420 mg QD. Patients in the ARDENT trial received a median of four prior lines of therapy with 100% receiving at least one novel hormonal therapy and 31% receiving at least one chemotherapy regimen. Patients in ARDENT were enrolled in one of four subgroups: Tumors with AR T878X and/or H875Y mutations and excluding AR L702H mutations and AR-V7 splice variants; Tumors with wild-type AR or AR alterations other than T878X, H875Y, L702H, AR-V7; Tumors with AR L702H mutations or AR-V7 splice variants, which are variants of AR that bavdegalutamide does not degrade preclinically; Biomarker agnostic tumors with only one prior NHA and no prior chemotherapy. The biomarker-agnostic subgroup is referred to as "less pretreated;" the three biomarker-defined subgroups are referred to collectively as "more pretreated" and received 1-2 prior NHA and no more than two regimens of chemotherapy. Efficacy measures are presented on a combined basis for patients in both the completed Phase 1 dose escalation trial and the interim analysis from the ongoing ARDENT Phase 2 dose expansion trial. Biomarker defined. In biomarker-evaluable patients treated at or above the RP2D and with tumors harboring AR T878X/H875Y mutations, the PSA50 response rate was 46% and the PSA decline of more than 30% response rate was 57%. Of seven RECIST-evaluable patients across the Phase 1/Phase 2 trial having tumors harboring AR T878X/H875Y mutations, two had confirmed durable confirmed partial responses. These patients were on treatment for approximately nine months and 10 months; the duration of treatment ranged from eight weeks to 44 weeks, with three of the seven patients continuing on treatment as of the data cutoff of December 20, 2021. Twelve of the 28 patients with AR T878X/H875Y-positive tumors received bavdegalutamide for greater than or equal to24 weeks, with nine patients ongoing as of the data cutoff. One confirmed and three unconfirmed RECIST responses were seen in patients with tumors lacking AR T878X/H875Y mutations. The "less pretreated" subgroup had a similar molecular profile - as assessed by circulating tumor DNA analysis - to the more pretreated, biomarker-defined subgroups in the ARDENT trial. These similarities included both AR variations and non-AR mutations frequently associated with poor outcomes. Six of the 27 patients had PSA50 reductions, and this PSA50 rate was similar to that observed collectively in the "more pretreated" subgroups. Four of the six "less pretreated" patients with PSA50 declines had tumors with AR T878X/H875Y mutations. Safety Bavdegalutamide had a manageable tolerability profile at the RP2D of 420 mg QD. The majority of treatment-related adverse events were Grade 1/2 and there were no Grade greater than or equal to4 TRAEs in the 138 patients treated at the RP2D. TRAEs that occurred in greater than or equal to10% of patients treated at the RP2D were nausea, fatigue, vomiting, decreased appetite, diarrhea, alopecia, AST increased, weight decreased, and anemia.TRAEs at the RP2D led to dose reduction in 11 patients and discontinuation in 12 patients. Anticipated 2022 Milestones for Bavdegalutamide: Discuss the potential accelerated approval path with the FDA 1H 2022; Finalize partnership for companion diagnostic 1H 2022; Initiate planned pivotal trial for patients with AR T878/H875 tumor mutations 2H 2022.

08:29 EST Arvinas announces Phase 1, interim Phase 2 data for bavdegalutamide - Arvinas announced completed Phase 1 and interim Phase 2 ARDENT data for bavdegalutamide, a novel PROTAC degrader targeting the androgen receptor. These data continue to provide evidence of anti-tumor activity and clinical benefit in patients with metastatic castration-resistant prostate cancer. Bavdegalutamide reduced prostate-specific antigen levels greater than or equal to 50% in 46% of patients with tumors harboring AR T878X and/ or H875Y mutations, and two of the seven Response Evaluation Criteria in Solid Tumors-evaluable patients in this group also had confirmed tumor responses. These results also demonstrated PSA declines and tumor regressions in patients without tumors harboring AR T878X/H875Y mutations, suggesting an opportunity to develop bavdegalutamide more broadly in prostate cancer.

08:27 EST Walmart sees Q1 operating income, EPS down low double digits to low teens - Sees Q2 and Q3 operating income and EPS up low to mid single digit rates.

08:25 EST Yumanity Therapeutics trading halted, news pending

08:20 EST Quoin Pharmaceuticals signs exclusive distribution agreement with Neopharm - Quoin Pharmaceuticals announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, Inc., has entered into an exclusive Distribution Agreement with Neopharm Medical Supplies, an exclusive distributor for leading medical and pharma manufacturers in Israel, for QRX003, the Company's investigational treatment for Netherton Syndrome, a rare and devastating genetic disease for which there is currently no available treatment or cure. Under the terms of the revenue sharing agreement, Neopharm gains exclusive rights to commercialize QRX003 in Israel. Quoin will be the exclusive supplier of QRX003 to Neopharm.

08:19 EST Walmart still seeing elevated levels of inflation, CFO says

08:18 EST Establishment Labs surpasses two million Motiva Implants in market - Establishment Labs Holdings announced that it has surpassed two million Motiva Implants in market. "Our journey to transform breast aesthetics and reconstruction has always been guided by putting women at the center of all of our efforts and by making innovation, science, and research the foundation of all of our products," said Juan Jose Chacon-Quiros, Establishment Labs CEO and Founder. "Having over two million Motiva implants now in the market is a testament to those efforts." "In the nine years from when we first commercialized Motiva, we delivered one million implants and now, just two years later, we have surpassed two million," said Dr. Heather Brennan, Head of US Commercial Operations. "Our commitment to women, ongoing development efforts, and advanced technologies have allowed us to win share as we expand our markets. I want to thank the entire Establishment Labs team and the growing group of surgeons who use our products for their support and partnership in helping us to achieve this important commercial milestone." Rosalyn Cole d'Incelli, Head of Clinical and Medical Affairs added, "Motiva implants have shown unsurpassed safety performance, with device-related clinical complication rates that remain less than 1%. Our eleven-year Post Market Surveillance Report, which includes all data from our internal registries and warranty claims as well as from international registries and peer-reviewed publications, consistently validates that we have raised the standard for what women should expect from the implants they choose."

08:17 EST NexPoint Real Estate Finance raises quarterly dividend 5.3% to 50c per share - NexPoint Real Estate Finance announced that its board of directors has declared a quarterly dividend of 50c per share of NREF common stock, up from 47.5c per share. The dividend will be payable on March 31 to stockholders of record on March 15.

08:15 EST Deutsche Telekom and RingCentral team to launch 'RingCentral X' - Deutsche Telekom (DTEGY) and its partner RingCentral (RNG) video meetings, collaboration, and contact center solutions announced an expansion of their partnership to offer customers 'RingCentral X powered by Telekom,' an end-to-end communications and collaboration solution. RingCentral X powered by Telekom includes RingCentral Message Video Phone, MVP, and will be available at the end of Q1'22 to all Deutsche Telekom business customers in Germany. RingCentral X powered by Telekom brings together RingCentral's team messaging, video meetings, and a cloud phone system on a single platform for customers of all sizes, enabling them to work from everywhere. Combining Deutsche Telekom's high quality access products, strong brand presence, and strength as a leading national network and service provider in Germany, with RingCentral's deep Unified Communications as a Service capabilities, gives customers in Germany a secure, reliable, and flexible business communications and collaboration solution. Accompanying the feature-rich UCaaS-solution of RingCentral, Deutsche Telekom offers its customers a wide range of individual services and a broad set of additional equipment to enhance their communication experience even further. Additionally, RingCentral's open API platform enables customers to integrate third party business applications across all necessary workflows with their global, multi-mode communications platform.

08:14 EST Beam says City of Los Angeles StreetsLA Division preview EV ARC street sweepers - Beam Global announced that the City of Los Angeles StreetsLA Division held an event demonstrating its new plug-in hybrid street sweepers and EV ARC sustainable EV charging systems at the StreetsLA North Hollywood Depot. A ribbon cutting ceremony was held February 15, 2022 to inaugurate the City's Center for Green Innovation. Beam CEO Desmond Wheatley was present alongside Mayor Garcetti, Congressman Cardenas and City officials where the EV ARC powered the new plug-in hybrid street sweepers.

08:14 EST Reinsurance Group announces longevity reinsurance transaction with NN Life - Reinsurance Group announced the completion of a longevity reinsurance transaction with NN Life, the largest life insurance company in the Netherlands. The reinsurance transaction covers approximately EUR 4B of underlying reserves. The transaction was effective December 31, 2021. Additional terms of the transaction are not being disclosed.

08:12 EST Kautex expands adoption of PowerFleet telematics solution - PowerFleet announced it will be further deploying its PowerFleet Enterprise industrial telematics solution to top global automotive supplier, Kautex, throughout 2022. Kautex has more than doubled the number of sites employing PowerFleet's telematics solutions on its forklifts in the past 12 months, which spans six countries and three continents. An additional nine sites are planned for implementation in 2022.

08:11 EST VirTra receives first order for multiple systems from Canada - VirTra has received its first order attributable to the standing offer it was awarded from the Government in Canada in December 2021. The standing offer is for VirTra to supply marksmanship and judgmental use of force simulation technology to various law enforcement, military police, border protection and corrections facilities throughout Canada. The initial order was placed by a Canadian law enforcement agency to receive multiple simulators and associated tools and accessories designed for simulator training. Part of the installation will also include hands-on training for system and hardware operation.

08:10 EST Walmart sees increasing pickup and delivery capacity by 35% this year

08:09 EST Walmart creating roles for more than 3,000 associate delivery drivers

08:07 EST Elys Game Technology extends sportsbook partnership with Santa Ana Star Casino - Elys Game Technology announced the extension of the sports wagering service agreement between the company's subsidiary USBookmaking, or USB, and the Santa Ana Star Casino Hotel in Santa Ana Pueblo, New Mexico. The agreement extends USB's contract to provide sports wagering services to Santa Ana's sportsbook. The Santa Ana Star Casino Hotel is the site of New Mexico's first sportsbook and offers event betting on all sports serviced by USB, including NFL, NBA, MLB, as well as College Football and Basketball through self-service kiosks and in-person ticket counters situated throughout the casino.

08:06 EST ZIM Integrated signs cooperation agreement amendment with the 2M Partners - ZIM Integrated Shipping Services announced that following its previous update on the extension of its operational cooperation agreement with the 2M partners, the parties have formally finalized the related documents in connection with their continued collaboration. The agreement is subject to regulatory approval.

08:05 EST Pixelworks announces Chairman of the Board retirement and succession plan - Pixelworks announced the Chairman of the Board of Directors, Richard Sanquini, has notified the company of his intent to retire and not stand for reelection at the company's 2022 annual meeting, at which time he will transition to a role of Chairman Emeritus. Sanquini will serve out his remaining term as a director and Chairman, which expires immediately prior to the Annual Meeting. The Board intends to nominate its current director Daniel Heneghan to succeed Sanquini as Chairman of the Board following the election of directors at the 2022 Annual Meeting. Heneghan has been an independent director on the Board since April 2006, and he currently serves as Chair of the Audit Committee as well as a member of the Corporate Governance and Nominating Committee.

08:04 EST Kore Group acquires Business Mobility Partners and SIMON IoT - Kore Group has acquired Business Mobility Partners and SIMON IoT, industry-leading mobility solution providers, to expand its services and solutions within the healthcare and life sciences industries. New York-based Business Mobility Partners, founded in 2016, has experienced growth in recent years as it has focused on delivering IoT enablement services to contract research organizations and remote patient monitoring customers. The combined entity will feature a portfolio of managed IoT services, including connectivity offerings coupled with access to pre-configured solutions. The acquisition also delivers a channel program with wireless carriers. The acquisition is subject to closing conditions and is expected to close in February, at which time Business Mobility Partners will operate under the name "Business Mobility Partners, a Kore Company". Business Mobility Partners and Simon IoT will continue to operate as standalone entities, while maintaining access to the full suite of Kore solutions and services.

08:04 EST Walmart 'finding a few places' to roll back prices

08:03 EST PolarityTE announces allowance of fourth U.S. patent - PolarityTE announced the U.S. Patent and Trademark Office recently issued a Notice of Allowance for U.S. Application No. 17/326,734 filed on May 21, 2021. This is the company's fourth patent allowance in the United States. The newly allowed claims are for compositions that relate to the company's minimally polarized functional unit technology in combination with a cryoprotectant.

07:52 EST Kyndryl Holdings and Nokia partner in global network and edge computing - Kyndryl (KD) and Nokia (NOK) announced a global network and edge computing alliance aimed at helping enterprise customers accelerate their digital transformations with LTE and 5G private wireless networking. The partnership builds on a private wireless connectivity project that yielded a solution combining Nokia Digital Automation Cloud application platform with Kyndryl's consulting, design, implementation and managed services. The solution is designed to support the move to Industry 4.0. By collaborating to provide solutions over LTE and 5G standards, Kyndryl and Nokia are addressing the marketplace opportunities that already utilize the industrial ecosystem available now with LTE, while paving the way for 5G enhancements in future 3GPP releases, with existing Nokia DAC 5G stand alone-ready private wireless solutions. Kyndryl and Nokia also plan to explore and develop new, integrated solutions and services for Edge Cloud, IP networking, Optics, Fixed Access, 4G and 5G Core and Network Operations software technologies that can address demand for mission-critical, industrial-grade wireless networking.

07:46 EST Legend Power on track to ship first 20 SmartGATE platforms by March 31 - Legend Power Systems announces that following delays due to supply chain constraints into the end of calendar 2021, the Company is on track to ship 20 units of its next generation SmartGATE Platform by the end of March 2022. Legend Power also announces that the first of these 20 units has now been installed and is exceeding savings performance expectations. The balance of the 20 units are in production and expected to ship prior to March 31, 2022.

07:41 EST Wayfair says Ashwin Rao joins company as chief science officer - Wayfair announced Ashwin Rao joined the company as chief science officer, and Niraj Nagrani as vice president of global supplier marketplace, pricing, catalog and merchandising technologies. Both leaders report to Wayfair's incoming chief technology officer, Fiona Tan, and join Wayfair's strong bench of technologists driving the future of shopping across all categories of home. "Technology underpins everything we do at Wayfair," said Tan, incoming CTO, Wayfair. "As an e-commerce and supply chain leader with suppliers and operations around the world, Wayfair is at the forefront of solving some of the most sophisticated and complex technological challenges facing retail. Ashwin and Niraj bring valuable expertise to the leadership team as we work together to drive the future evolution of our customer experience across online and physical retail."

07:39 EST Avalo Therapeutics appoints Garry Neil as CEO, Chris Sullivan as CFO - Avalo Therapeutics announced a leadership transition. On February 14, 2022 and effective immediately, the Company's Board of Directors appointed Garry Neil, Chief Scientific Officer, as CEO and Chris Sullivan, Chief Accounting Officer, as CFO. The Company's research and development group will continue to report to Dr. Neil. Mike Cola and Schond Greenway have stepped away from their prior roles as CEO and CFO, respectively, to pursue other interests.

07:37 EST Arrowhead announces interim results from AROHIF21001 for ccRCC - Arrowhead Pharmaceuticals announced positive interim results from AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the company's investigational RNA interference therapeutic being developed as a treatment for patients with clear cell renal cell carcinoma . The data presented provide initial proof of target engagement based on reductions in hypoxia inducible factor-2 alpha expression, as well as an acceptable safety profile in response to escalating doses of ARO-HIF2. The data are being presented by James Brugarolas, M.D., Ph.D, Professor at University of Texas Southwestern Medical Center and investigator in the study, in a poster presentation at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), being held February 17-19, 2022, in San Francisco, CA and online.

07:36 EST Camping World to acquire Bowling RVs in Iowa - Camping World announced an agreement to acquire Bowling RVs in Ottumwa, Iowa. The acquisition is anticipated to close next month and will be the company's fourth location in the state. The facility will transition to the Camping World brand at closing. The SuperCenter will include a wide range of new and used RVs for sale in addition to a full assortment of RV and outdoor products and accessories and RV service, maintenance, and repair.

07:35 EST Zai Lab receives Breakthrough Therapy Designation for repotrectinib in China - Zai Lab announced that the Center for Drug Evaluation of the National Medical Products Administration granted Breakthrough Therapy Designation for investigational repotrectinib for the treatment of patients with ROS1-positive metastatic non-small-cell lung cancer who have not been treated with a ROS1 tyrosine kinase inhibitor. The breakthrough therapy designation for repotrectinib was supported by the initial data from both global and Chinese TKI-naive ROS1-positive NSCLC patients enrolled in the Phase 1/2 TRIDENT-1 study.

07:34 EST AutoNation says Q4 used vehicle retail unit sales increased 21% - AutoNation's fourth quarter and full year 2021 used vehicle retail unit sales increased 21% and 26% respectively, compared to the prior year periods. This strong performance was driven by exceptional used vehicle sourcing, a broad selection of inventory, a proven operating model, demonstrated digital scale, and an admired brand. AutoNation will continue to expand its used vehicle retail business, leveraging its existing capabilities and AutoNation USA growth plan, coupled with rich data and analytics. These core elements will accelerate growth and further differentiate the company in the used vehicle market.

07:28 EST Lee Enterprises urges shareholders to vote for director nominees - Lee Enterprises, Incorporated released a detailed presentation to investors ahead of its 2022 Annual Meeting of Shareholders, scheduled for March 10. The company said, "The presentation outlines Lee's Three Pillar Digital Growth Strategy, which is delivering strong results and positions Lee to drive more than $435 million of recurring, sustainable digital revenue by 2026. It also highlights the strength and diverse skills and perspectives of the Lee Board of Directors. The presentation encourages Lee shareholders to vote for the re-election of three critical members of Lee's leadership team, including Lee's Chairman, Lead Independent Director and Chief Executive Officer."

07:25 EST TriNet commences modified Dutch auction tender offer for up to $300M in stock - TriNet has commenced a modified "Dutch auction" tender offer to purchase for cash up to $300M in value of its common stock at a price per share not less than $83.00 and not greater than $97.00, less any applicable withholding taxes and without interest, using available cash on hand. On February 16, the closing price of the Common Stock was $81.22 per share. The Tender Offer will expire at the end of the day on March 17 unless extended or terminated. Assuming that the conditions to the Tender Offer are satisfied or waived and the Tender Offer is fully subscribed, if the purchase price per share is $83.00, the company would purchase 3,614,457 shares and if the purchase price per share is $97.00, the company would purchase 3,092,783 shares, representing approximately 5.5% and 4.7%, respectively, of the company's outstanding Common Stock. The Tender Offer will not be contingent upon any minimum number of shares being tendered or any financing conditions.

07:23 EST Enanta announces human challenge study data published in NEJM - Enanta announced that data from its Phase 2 human challenge study has been published in The New England Journal of Medicine, or NEJM. The Phase 2a study was a randomized, double-blind, placebo-controlled, human challenge study in healthy adult subjects inoculated with RSV. Once RSV infection was confirmed, subjects were randomized to receive either a once-daily, or QD, 600 mg dose of EDP-938, a single 500 mg loading dose, or LD, followed by a 300 mg twice daily, or BID, dose of EDP-938, or placebo for five days. The primary endpoint was change in viral load (determined by RT-qPCR), as measured by the area under the curve, or AUC, from initial dose through Day 12 in the intent-to-treat infected population. A key secondary endpoint measured AUC reduction in total symptom score. The NEJM publication highlighted results from the Phase 2 human challenge study in which the primary efficacy endpoint was met with a highly statistically significant reduction in viral load AUC was observed for each of the EDP-938 dosing groups as compared with placebo. EDP-938 lowered viral load AUC to 203.95 +/- 173.50 hours x Log10 copies/mL in the QD arm and 217.71 +/- 217.55 hours x Log10 copies/mL in the BID arm, compared to 790.15 +/- 408.80 hours x Log10 copies/mL in the placebo arm. There was no statistically significant difference between the two EDP-938 dosing groups. For the key secondary efficacy endpoint, a highly statistically significant reduction was observed in total symptom score for each of the EDP-938 dosing groups. There was no statistically significant difference between the two EDP-938 dosing groups. EDP-938 demonstrated good pharmacokinetics, and mean trough levels of drug were maintained at approximately 20-40x above the in vitro EC90 for RSV-infected human cells. Overall, EDP-938 was generally safe and well-tolerated. EDP-938 demonstrated a favorable safety profile over five days of dosing through Day 28 of follow-up, comparable to placebo for both dosing groups. There were no serious adverse events and no discontinuations of study drug.

07:21 EST McEwen Copper appoints Michael Meding as VP, Andes Corporacion Minera - McEwen Copper (MUX) is pleased to announce that Michael Meding has joined as Vice President of Andes Corporacion Minera SA. in Argentina. Mr. Meding is accountable for the overall direction and management of the Los Azules copper project in San Juan. He will play a significant role in taking McEwen Copper through its next phases of technical studies, upcoming IPO, and development as a global model for environmentally and socially responsible green mining. Mr. Meding has over 20 years of international experience, primarily with major mining companies such as Barrick Gold (GOLD) and Trafigura, including extensive experience with project development and operations in Argentina.

07:19 EST Walmart reports Q4 U.S. comparable sales up 5.6%

07:16 EST Evelo Biosciences doses first patient in Phase 2 trial of EDP1815 - Evelo Biosciences announced that the first patient has been dosed in EDP1815-207, its Phase 2 randomized clinical trial of EDP1815 for the treatment of patients with mild, moderate, and severe atopic dermatitis.Topline results from the Phase 2 clinical trial are expected in 1H 2023.

07:15 EST Clever Leaves begins sales of cannabis extracts in Germany - Clever Leaves Holdings announced the importation of its first German high-quality standards compliant commercial extracts that will soon be available for distribution by its partner in Germany Ethypharm. The company said, "We are one of the first to successfully complete a commercial shipment of Colombian-manufactured high-CBD pharmaceutical product to Germany available for patients in pharmacies under prescription." Following a March 2021 supply agreement signed by the two companies providing Ethypharm access to Clever Leaves Holdings EU GMP certified cannabis extracts, the shipment includes two products: a 100 mg CBD with 3 mg THC per gram formulation and a 200 mg CBD with 6 mg THC per gram formulation. Partnering with an established pharmaceutical company like Ethypharm allows Clever Leaves Holdings to enter the German pharmaceutical market more broadly, which may accelerate the Company's expansion into the gradually expanding European cannabis market.

07:13 EST Walmart raises annual dividend 2% to $2.24 per share - The board of directors of Walmart has approved an annual cash dividend for fiscal year 2023 of $2.24 per share, an increase of approximately 2% from the $2.20 per share paid for the last fiscal year. The fiscal year 2023 annual dividend of $2.24 per share will be paid in four quarterly installments of 56c per share. "We're proud of our track record of returning meaningful cash to shareholders and are pleased to be increasing our annual dividend for the 49th consecutive year," said Brett Biggs, executive vice president and CFO at Walmart Inc.

07:10 EST Alkermes presents new data on nemvaleukin alfa monotherapy - Alkermes presented new data from the ongoing phase 1/2 ARTISTRY-1 clinical trial for nemvaleukin alfa, the company's novel, investigational, engineered interleukin-2 - IL-2 - variant immunotherapy. The data were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium. The presentation includes updated efficacy and safety data from the monotherapy arm of ARTISTRY-1, in which single-agent, anti-tumor activity of intravenous nemvaleukin was observed in patients with advanced renal cell carcinoma, including patients who were checkpoint inhibitor-pretreated. Data highlights from the ASCO GU poster presentation include: nemvaleukin monotherapy induced robust expansion of CD8+ T and natural killer cells, with minimal effect on regulatory T cells; among 23 evaluable patients, four achieved a partial response - one unconfirmed - and three of these patients continued on monotherapy; decreases in target lesions of up to 60% were observed; stable disease was observed in 10 patients; safety among these patients with advanced RCC was consistent with that which was previously reported for the IV nemvaleukin monotherapy-treated population in the ARTISTRY-1 study. Fever, chills, nausea and anemia were the most frequently reported adverse events, regardless of causality. Chills and anemia were the most commonly reported treatment-related AEs of grade greater than or equal to3. There were no deaths due to treatment-related AEs.

07:10 EST Nxt-ID names Mark Archer as CFO - NXT-ID announces it has appointed Mark Archer as CFO, and Rafael Saavedra as VP of Engineering. The executives will join the leadership team and be responsible for directing and managing NXT-ID's patented IoT technology that helps improve the lives of seniors. Archer brings 30 years CFO experience in public and private companies, both consumer and technology focused. He has provided financial leadership to companies, ranging from small startups to those with multi-billion dollar revenue streams, while also working with many top tier venture capital and private equity firms. He has held executive positions in many well-known businesses including Jamba Juice, WSS, SmartBee Controllers and Denny's. Archer, a partner at FLG Partners, a world-renowned partnership of experienced CFOs delivering to CEOs and boards high-value, interim and permanent leadership, previously served as the company's interim CFO.

07:09 EST Lyra Therapeutics names Harlan Waksal, MD, as Executive Chairman - Lyra Therapeutics announced the appointment of Harlan Waksal MD, as Executive Chairman. Dr. Waksal most recently served as President, CEO and Member of the Board of Directors of Kadmon Holdings prior to its acquisition by Sanofi in November 2021. With more than 30 years of scientific, clinical development, business development and management experience in the industry, Dr. Waksal holds a successful track record of founding, scaling and advising growth-oriented companies.

07:08 EST Perella Weinberg Partners announces $100M share repurchase authorization - On February 16, 2022, the Company's Board of Directors authorized the repurchase of shares of the Company's Class A common stock in an amount up to $100 million, enabling the Company to opportunistically return value to shareholders. The authorization does not require the purchase of any minimum number of shares. Based on the closing price of PWP shares as of February 16, 2022, the full authorization would currently represent approximately 20% of the Company's outstanding Class A common stock.

07:07 EST Baidu brings Apollo Go robotaxi service to downtown Shenzhen - Baidu Apollo's ride-hailing service platform Apollo Go has launched trial operation in Shenzhen's Nanshan District, providing autonomous robotaxi services to Shenzhen commuters. Shenzhen is the seventh city where Baidu has introduced its robotaxi ride services in China, following Beijing, Shanghai, Guangzhou, Chongqing, Changsha, and Cangzhou. Shenzhen's Nanshan District, home to top tech companies including Tencent and Huawei, is one of the most densely populated areas in south China. The launch of Baidu's robotaxi services is set to drive further developments in autonomous driving in Shenzhen and accelerate the development of local intelligent connected vehicles, underscoring Baidu's continuous efforts and ambition to lead the transformation of intelligent transportation in China. Users will be able to hail a robotaxi via the Apollo Go app at one of approximately 50 stations, with daily operating hours from 9am to 5pm. Services will be centered around key downtown spots such as Shenzhen Talent Park, covering surrounding residential areas, commercial areas, entertainment and cultural areas and other high-frequency transport destinations. The service area is set to expand to more than 300 stations by the end of 2022, meeting the ever-growing daily travel needs of Shenzhen residents.

07:06 EST Walmart reports Q4 ecommerce sales up 1% - Walmart U.S. eCommerce sales grew 1% and 70% on a two-year stack. Sam's Club comp sales increased 10.4%, and 21.2% on a two-year stack. Membership income increased 9.1%. Walmart International net sales were $27.0 billion, a decrease of $7.9 billion, or 22.6%, negatively affected by $10.1 billion due to divestitures.

07:06 EST Stepan Company increases quarterly dividend to 33.5c per share - The board of directors of Stepan Company declared a quarterly cash dividend on the company's common stock of 33.5c per share. The dividend is payable on March 15 to common stockholders of record on March 4. The company increased its quarterly cash dividend in Q4 by 30c per share, marking the 54th consecutive year that the company has increased its cash dividend to stockholders.

07:04 EST Stepan CEO F. Quinn Stepan to transition out of role, Scott Behrens to succeed - Stepan Company announced that F. Quinn Stepan, Jr. will retire as CEO of the company on April 25. Stepan will continue to serve as non-executive chairman of the board assuring an effective transition. Scott Behrens, currently president and COO, will succeed him as president and CEO. The company expects that Behrens will be nominated for election to the board of directors at the 2022 annual meeting. Behrens, who was named president and COO in 2021, brings global industry and leadership experience.

07:01 EST Bristol-Myers' sBLA for Breyanzi in lymphoma accepted by FDA for priority review - Bristol Myers announced that the FDA has accepted its supplemental Biologics License Application - sBLA - for Breyanzi - lisocabtagene maraleucel -, a CD19-directed chimeric antigen receptor T cell therapy, to expand its current indication to include earlier use of Breyanzi for the treatment of adults with relapsed or refractory large B-cell lymphoma after failure of first-line therapy. The FDA has granted the application Priority Review and assigned a Prescription Drug User Fee Act goal date of June 24. The sBLA is based on results from the Phase 3 TRANSFORM trial. Results showed Breyanzi provided highly statistically significant and clinically meaningful improvements in event-free survival, complete responses and progression-free survival, and a positive trend in overall survival in patients with LBCL whose disease was primary refractory or relapsed within 12 months after first-line therapy compared to standard of care.

06:51 EST Reliance Steel raises quarterly dividend 27.3% to 87.5c per share - Payable on March 25 to stockholders of record as of March 11.

06:39 EST BitNile's Gresham Worldwide booked new orders exceeding $10.2M in Q4 - BitNile Holdings announced that its global defense subsidiary, Gresham Worldwide, booked orders for new business exceeding $10.2M in the fourth quarter ended December 31, 2021, a 36% increase over the $7.5M in new business booked in Q3 2021.

06:36 EST Babcock & Wilcox's Environmental segment awarded $13M ash reduction contract - Babcock & Wilcox's B&W Environmental segment has been awarded a contract for approximately $13M to design and supply equipment to reduce the environmental impact of ash at a U.S. power plant. B&W Environmental will design, manufacture and supply a state-of-the-art Allen-Sherman-Hoff(R) submerged grind conveyor ash-handling system and related equipment as a retrofit to the plant's existing ash slurry system to meet zero-discharge bottom ash removal requirements.

06:34 EST Airbus board to propose dividend of EUR 1.50 per share - The Board of Directors will propose the payment of a 2021 dividend of EUR 1.50 per share to the 2022 Annual General Meeting. The payment date is 21 April 2022.

06:33 EST CommScope CEO says will not proceed with planned spin-off of Home Networks - Chuck Treadway, President and CEO said, "In light of the ongoing impact of supply chain pressures on the Home Networks business that began in the summer of 2021, including semiconductor supply decommits and extended component lead times, we have determined that market conditions are not currently conducive to proceeding with the planned spin-off of Home Networks into an independent company in the second quarter of 2022. We remain committed to the merits of strategically separating Home Networks from CommScope, and still plan to execute on that strategy when clear evidence of a more normalized and predictable supply environment emerges."

06:24 EST Nestle sees sustained mid single digit organic sales growth - Nestle's mid-term outlook includes: sustained mid single-digit organic sales growth. Continued moderate underlying trading operating profit margin improvements. Continued prudent capital allocation and capital efficiency improvements.

06:16 EST Radware to acquire the business of SecurityDAM for $30M - Radware announced a strategic initiative to accelerate the growth of its cloud security services business. As part of this initiative, Radware will acquire the business of SecurityDAM, its DDoS scrubbing centers provider. In addition, Radware plans to grow its innovation center in India, as well as further expand its cloud network footprint and capacity, and its cloud services division, including its technology, operations, and headcount. These actions reflect the company's ongoing commitment to provide customers with the highest level of cyber security services and protection. Under the terms of the asset purchase agreement, Radware acquired SecurityDAM's technology and operations for $30M with contingent payments of up to $12.5M. The company expects the acquisition to be accretive to earnings on a non-GAAP basis in 2023.

06:11 EST Alta Fox Capital nominates five candidates for election to Hasbro board - Alta Fox Capital Management, the beneficial owner of approximately 2.5% of the outstanding shares of Hasbro, announced that it has nominated five highly qualified and independent candidates for election to the company's Board of Directors at the 2022 Annual Meeting of Shareholders. In connection with its nomination, Alta Fox issued an open letter to its fellow shareholders and released a detailed 100-page presentation that can be accessed at www.FreeTheWizards.com.

06:09 EST TRI Pointe expects to deliver 900-1,200 homes in Q1 - For the first quarter of 2022, the company anticipates delivering between 900 and 1,100 homes at an average sales price between $650,000 and $660,000. The company expects its homebuilding gross margin percentage to be in the range of 25.0% to 26.0% for the first quarter of 2022 and anticipates its SG&A expense as a percentage of home sales revenue will be in the range of 13.0% to 13.5%. Lastly, the company expects its effective tax rate for the first quarter of 2022 to be in the range of 25.0% to 26.0%.

06:06 EST Spotify acquires Podsights, Chartable podcast analytics companies - Spotify on Wednesday announced the acquisition of two podcast technology companies, Podsights and Chartable. The company said: "With the acquisition of Podsights, Spotify will be able to help advertisers understand how podcast ads drive actions that matter to their businesses. Over time, we plan to extend these measurement capabilities beyond podcasts to the full scope of the Spotify platform, including audio ads within music, video ads, and display ads... And now with the acquisition of Chartable, we will be further enhancing Megaphone's suite of tools with the integration of Chartable's audience insights and cutting-edge promotional tools, SmartLinks and SmartPromos. These tools will make it easier for publishers to turn audience insights into action and expand their listenership while ultimately growing their businesses." Reference Link

06:05 EST Mednax sees 2022 adjusted EBITDA at least $270M

05:18 EST Paysafe expands partnership with BetWildwood - Paysafe announced its expanded partnership with BetWildwood, the official online sportsbook of Wildwood Casino in Colorado. BetWildwood has integrated Paysafe's new Skrill USA digital wallet, upgrading its existing Skrill wallet to streamline depositing and payouts for its players as well as support broader customer acquisition and retention.